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Abstract 
 
Engineering of Candida antarctica lipase B for the kinetic resolution of α-halo esters 
 
Shu-Ling Tang 
 
PhD 
 
University of Manchester 
 
Retrosynthetic analyses of several therapeutic targets leads to the possibility of using 
enantiopure α-bromopropionic acid as a starting material. Therapeutic targets include (S)-
Keppra, an anti-epileptic drug, and (R)-Tiopronin, used to prevent kidney stones. 
Enantiopure α-bromoacids also provide an efficient way for the synthesis of numerous 
other chiral starting materials. α-Fluoropropionic acid was also proposed as a substrate for 
the synthesis of enantiopure agrochemicals.  
 
Kinetic resolution via enzymatic methods was proposed and development of a scalable 
biocatalytic process to access 2-bromopropionic acid, 2-fluoropropionic acid and their 
esters in a single enantiomeric form with a high enantiomeric excess was undertaken. 
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Initial screening results with a commercially available lipase kit indicated that Candida 
antarctica lipase B (Cal B) was active towards kinetically resolving both the substrates, 2-
bromopropionic acid and 2-fluoropropionic acid. The Cal B gene was amplified from its 
pPIC9 construct and molecular biology techniques were used to generate two new 
constructs, pET16b and pET SUMO, suitable for the expression of Cal B from Escherichia 
coli. Various conditions such as temperature and incubation time were optimised for the 
production of soluble and active Cal B in two strains of E. coli. Three optimised conditions 
were found and the different preparations of Cal B were characterised using the p-
nitrophenyl butyrate assay. Molecular modelling studies of the docking of both substrates 
into a known Cal B X-ray crystallographic structure for the enhancement of 
enantioselectivity were completed. Several residues namely Thr40, Asp134, Thr138, 
Gln157, Ile189, Val190, Leu278 and Ile285 were identified for the rational design of 
mutants of Cal B with enhanced activity or enantioselectivity. Site directed mutagenesis 
was used to generate a focused library of mutants with single point mutations. Mutants 
with higher specific activity and opposite enantiopreference were identified. 
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1 Introduction 
 
1.1 Chirality in nature 
 
Organisms in nature have evolved primarily to use L-amino acids and D-sugars.
1a
 The 
inherent chirality of these simple building blocks of life means that their asymmetry is 
passed on to proteins and carbohydrates. As a result, we have evolved to incorporate 
asymmetry in all aspects of our life from our hands to the receptors in our noses. Our noses 
are able to distinguish between the enantiomers (R)-(−)-carvone (R)-1 which has the smell 
of caraway seeds and  (S)-(+)-carvone (S)-1, which smells like spearmint (Figure 1.1).
1b,2
  
 
O
(R)-1 (S)-1
O
 
           
Figure 1.1: (R)-Carvone (R)-1 and (S)-carvone (S)-1. 
 
1.2 Enantiomers of drugs 
 
The absolute stereochemistry of a molecule is biologically relevant as enantiomers are able 
to initiate different effects by occupying the three dimensional space of a receptor 
differently. Consider the two enantiomers of Thalidomide 2, a sedative hypnotic and an 
anti-emetic, and their effects (Figure 1.2).
3
 Whilst (R)-Thalidomide (R)-2 is harmless and 
has various beneficial pharmacological properties, (S)-Thalidomide (S)-2 is teratogenic.
4
 
The devastating effects of the (S)-enantiomer (S)-2 and the racemisation of (R)-
Thalidomide (R)-2 under physiological conditions were only found after the birth of 
abnormal children.
4-6
  
 
Enantiomers of a compound have the same physical properties except for their optical 
activity when in an achiral environment, but in a chiral environment they will have 
different properties including pharmacokinetics and pharmacodynamics. Binding sites on 
 13 
proteins are three dimensional and the way an enantiomer fits into that site will depend on 
its orientation in space. Until recently the anaesthetic and analgesic, Ketamine 3, was used 
in its racemic form.
7,8
 Even though both enantiomers of ketamine have anaesthesia 
properties, the (S)-enantiomer (S)-3 is significantly more potent than the (R)-enantiomer 
(R)-3 (Figure 1.3).
8,9
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Figure 1.2: Enantiomers of Thalidomide 2.
4 
 
NH
Cl
O
(S)-3
NH
Cl
O
(R)-3  
                                     
Figure1.3: Enantiomers of Ketamine 3.
9
 
 
In 1987 the U.S. Food and Drug administration (FDA) released a policy statement for the 
recommendation of the synthesis of chiral drugs and both the FDA and European 
Committee for Proprietary Medicinal Products have specified that both enantiomers of a 
drug need to be physiologically assessed.
5 
Previously the physiological effects of different 
enantiomers may have been ignored but now the distinct advantages of single enantiomer 
drugs are being recognised. Lower dosages, reducing adverse drug interactions and 
improved efficacy are advantages of single enantiomer drugs as well as better economical 
and environmental efficiency.
10-12
 Enantiopure agrochemicals are also important as an 
inactive enantiomer may interact adversely with the ecological system. Both in the 
pharmaceutical and agrochemical industries, the inactive enantiomer can be considered an 
 14 
impurity or pollutant and regulatory agencies increasingly want toxicological reports for 
impurities constituting more than 1% of the content.
13,14
 
 
1.2.1 Chiral pool asymmetric synthesis 
 
The chiral pool is a source of natural products that are used as starting materials for the 
synthesis of target molecules, chiral auxiliaries and chiral ligands. Homochiral starting 
materials that are needed can sometimes be immediately apparent in a target molecule like 
aspartame 4. The dipeptide is synthesised from (S)-aspartic acid (S)-5 and (S)-
phenylalanine (S)-6 (Scheme 1.1).
1c,15
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Scheme 1.1: Retrosynthesis of aspartame 4.
1c,15 
 
Many steps may also be required to convert the chiral pool compound to the desired target 
as in the case of (S)-(-)-ipsenol (S)-16, a component of the pheromone of male bark beetles 
of the genus Ips. A total of seven steps were needed to convert the chiral pool starting 
material, (S)-leucine (S)-7 to (S)-(-)-ipsenol (S)-16 (Scheme 1.2).
1c,15 
 
Although in general extraction of chiral starting materials from nature is economical, on 
some occasions only one enantiomer of the desired starting material is available from the 
chiral pool or the difference in cost is substantial. 
 
 15 
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Scheme 1.2: Synthesis of (S)-(-)-ipsenol (S)-16 from (S)-leucine (S)-7.
1c,15
 
Reagents and conditions: (i) (a) NaNO2, H2O, H2SO4, 0 °C, 2 h, (b) rt, overnight (ii) (a) LiAlH4, THF, 0 °C, 1 
h, (b) rt, overnight (iii) TsCl, 0 °C, (iv) KOH, H2O, ethylene glycol, (v) (a) diethyl malonate, NaOEt, EtOH, 
NaCH(CO2Et)2, reflux, 5 h, (b) KOH, reflux, 1 h, (c) H2SO4 (aq.), (vi) CH2O aq., Et2NH, 80-90 °C, 0.5 h, (vii) 
NaBH4, C6H5SeH, EtOH, rt, 2 h, (viii) i-Bu2AlH, dry THF, - 60 – 50 °C, 1 h, (ix) 
triphenylmethylphosphonium bromide, NaCH2SOMe, dry DMSO, rt, 3 h.  
 
1.2.2 Resolution 
 
Resolution is the separation of a racemic mixture into its constituent enantiomers by using 
a chiral resolving agent. The reaction of a racemate with a chiral compound affords 
diastereoisomers which can be separated by their different physical properties i.e. 
chromatography or recrystallisation. This technique was used for the resolution of racemic 
3-(N,N-dimethylamino)-1-(2-thienyl)propan-1-ol rac-17 in the industrial scale synthesis of 
Duloxetine (S)-20, an antidepressant. A saturated solution of racemic 3-(N,N-
dimethylamino)-1-(2-thienyl)propan-1-ol rac-17 was seeded with (S)-mandelic acid (S)-18, 
 16 
in which the diastereoisomeric salt (S)-19 precipitated. The filtrate, containing the (R)-
enantiomer (R)-17, was racemised to circumvent the disadvantage of 50% yield. Once the 
crystallised (S)-19 was filtered, it was hydrolysed back to the alcohol (S)-17. (Scheme 
1.3).
16
 Resolution using diastereoisomeric salts allow the formation of ionic compounds 
that can be separated by their solubility. Resolution can also be done using the weakest of 
forces like hydrogen bonds and van der Waals which are used in chromatography. 
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Scheme 1.3: Resolution of racemic alcohol rac-17.
16
 
Reagents and conditions: (i) (a) PhMe, MeOH, rt, (b) 80 °C, 0.5 h, (c) cool to rt, 1 h, (ii) NaOH, H2O. 
 17 
1.2.3 Auxiliary controlled stereoselectivity 
 
A chiral auxiliary is an enantiomerically pure compound that is covalently attached to the 
substrate to impart stereoselectivity in a reaction. As with a resolution, the reaction of a 
chiral compound with an achiral compound results in a diastereoselective reaction and then 
the components can be separated. An advantage of chiral auxiliaries is that they can be 
recycled. Some common auxiliaries that are used are the Evans auxiliary 21 and the 
norephedrine derived auxiliary 22 (Figure 1.4).
1c,17
  
 
OHN
O
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21 22
 
 
Figure 1.4: Evans auxiliary 21 and the norephedrine derived auxiliary 22.
1c,17
 
 
The Evans chiral auxiliary and its many derivatives have been utilised in asymmetric 
reactions such as Michael additions
18,19
 and Diels-Alder reactions
20,21
.  An example of a 
chiral auxiliary being used in a Diels-Alder reaction allowed the synthesis of the single 
enantiomer 28 (Scheme 1.4). The synthesis involves the in situ generation of the chiral 
auxiliary 24 from (1S,2R)-1-amino indan-2-ol 23. Reaction of the chiral auxiliary 24 with 
the acrylic acid dienophile 25 affords the auxiliary–dienophile 26. The Lewis acid 
coordinates the auxiliary–dienophile complex 26 and piperylene 27 is positioned above the 
complex as the auxiliary 24 blocks the diene from approaching the bottom face of the 
dienophile thus making the reaction diastereoselective.
21
  
 
 18 
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Scheme 1.4: Diels Alder reaction using the norephedrine derived auxiliary.
1c,21
 
Reagents and conditions: (i) triphosgene, (ii) triethylamine, LiBr, acryloyl chloride, EtOAc, 4-6 h, (iii) 
CH2Cl2, Et2ACl. 
 
1.2.4 Reagent controlled stereoselectivity 
 
An alternative to attaching a chiral unit to the starting material is to use a chiral reagent to 
impart stereoselectivity. For example, a chiral reducing agent such as the Corey, Bakshi 
and Shibata (CBS) reagent 29 can be used to reduce acetophenone 30 selectively to (R)-1-
phenylethanol (R)-31 (Scheme 1.5).
22
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O
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OHBH3
N
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H
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Ph
29 30 (R)-31
97% e.e.  
 
Scheme 1.5:Reduction of acetophenone 30 to 1-phenylethanol 31 selectively using the 
CBS reagent 29.
22
 
Reagents and conditions: THF, 25 °C, 1 minute. 
 
 19 
Catalysts that result in a stereoselective reaction such as Sharpless‟ titanium 
tetraisopropoxide
23,24
 and Jacobsen‟s25 catalyst are expensive and although they are only 
required in small quantities they are still only available for a few reactions such as 
epoxidation and dihydroxylation.  
 
1.3 Pharmacologically active compounds 
 
1.3.1 Retrosynthetic analyses of (S)-Keppra (S)-32 and (R)-Tiopronin (R)-34 
 
Retrosynthetic analysis of several therapeutic targets leads to the possibility of using (R)-2-
bromobutyric acid (R)-33 and (S)-2-bromopropionic acid (S)-35 as starting materials. 
Therapeutic targets include (S)-keppra (S)-32, an anti epileptic drug and (R)-tiopronin (R)-
34, used to prevent kidney stones (Scheme 1.6). 
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Scheme 1.6:  Retrosynthetic analyses of several therapeutic targets. 
 
1.3.2 (S)-Keppra (S)-32 
 
Epilepsy is a neurological disorder characterised by periodic seizures. Epilepsy affects 
people of all ages and around 50 million people worldwide have been diagnosed with the 
disorder. The spontaneous seizures are symptoms of abnormal, excessive or synchronous 
 20 
neuronal activity in the brain.
26
 In most diagnosed cases of epilepsy there is no known 
cause and treatment consists of controlling the seizures with anti-epileptic drugs (AEDs). 
(S)-Keppra (S)-32 is an AED, which was found to have a different mode of action; acting 
on the synaptic vesicle protein SV2A in the brain rather than on the ion channels or 
postsynaptic receptors.
27
 As traditional AEDs do not always control seizures in all patients, 
identification of this new mechanism of action further adds to the number of possible 
successful therapeutic strategies. 
 
There are many asymmetric syntheses of (S)-Keppra (S)-32 reported including a chiral 
pool synthesis and one involving a kinetic resolution. The chiral pool synthesis uses L-
methionine
28
 or (S)-2-aminobutyramide hydrochloride (S)-36
29,30
 (Scheme1.7). 
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Scheme 1.7: Chiral pool synthesis of (S)-Keppra (S)-32 from (S)-2-aminobutyramide 
hydrochloride (S)-36.
29,30 
Reagents and conditions: (a) ClCO(CH2)3Cl, K2CO3, MeCN, (b) TBAB, DCM, KOH, 0 °C. 
 
Another synthesis of (S)-Keppra (S)-32 reported is the chromatographic resolution of the 
racemate Etiracetam rac-32 (Figure 1.5) by employing silica gel supporting amylose tris-
(3,5-dimethylphenylcarbamate) (Daicel, Chiralpak
®
 AD) as the stationary phase.
31 
 
NH2
O
N
O
rac-32
 
Figure 1.5: Etiracetam rac-32. 
 21 
A synthesis from a common intermediate allows facile development of analogues and one 
such method was reported for the synthesis of (S)-Keppra (S)-32. A chiral auxiliary (S)-37 
was used for the deracemisation of 2-bromobutanoic acid rac-33.
32
 The synthesis had an 
overall yield of 65% and involved the coupling of the chiral auxiliary, (S)-N-
phenylpantolactam (S)-37, to racemic 2-bromobutanoic acid rac-33 (Scheme 1.8).  
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Scheme 1.8: Coupling of the (S)-N-phenylpantolactam chiral auxiliary (S)-37 to racemic 2-
bromobutanoic acid rac-33. 
Reagents and conditions: (a) Cl2SO, (b) (S)-37, CH2Cl2, Et3N, -20 °C, 4 h. 
 
Cleavage of the chiral auxiliary from intermediate (α,R,3S)-38 affords enantiopure 2-
bromobutanoic acid (R)-33. Nucleophilic substitution of 2-bromobutanoic acid (R)-33 with 
2-pyrrolidonone via an SN2 mechanism would afford the (S)-2-(2-oxopyrrolidin-1-yl)-
butanoic acid (S)-39 which upon amidation
33
 yields (S)-Keppra (S)-32. Only a slight loss in 
enantiopurity under the amidation conditions was observed (Scheme 1.9).
32,34  
 
The next generation of AEDs, Brivaracetam 40 and Seletracetam 41, have already been 
developed and are analogues of (S)-Keppra (S)-32. They can by synthesised from the 
common intermediate (R)-2-bromobutanoic acid (R)-33. Brivaracetam 40 exhibited a 13-
fold increase in affinity
35
 over (S)-Keppra (S)-32 but Seletracetam 41 was the most potent 
of the three AEDs
37
 (Figure 1.6).
35-37
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Scheme 1.9: Synthesis of (S)-Keppra (S)-32 from (R)-2-bromobutanoic acid (R)-33 after 
cleavage of the chiral auxiliary from intermediate (α,R,3S)-38.32-34 
Reagents and conditions: (i) LiOH, H2O2, THF, 0 °C, 5 h, (ii) NaH, 2-pyrrolidinone, THF, rt, overnight, (iii) 
(a) ClCO2Et, CH2Cl2, 0 °C, 0.5 h, (b) NH4OH, rt, 16 h. 
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Figure 1.6: Next generation of anti-epileptic drugs, Brivaracetam 40 and Seletracetam 41. 
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1.3.3 (R)-Tiopronin (R)-34 
 
Tiopronin 34 is a pharmaceutically important thiol compound with a range of biological 
properties. It is used to treat hepatic disorders
38,39
, cystinuria
40,41
, rheumatoid arthritis
42-44
 
and can be used as a mucolytic in respiratory disorders
44,45
 and is also effective against 
radiation-induced damages, even at low doses
46
. The sulfhydryl side chain is responsible 
for its many actions. Tiopronin 34 is capable of liberating its SH group, which has an 
important physiological function in the body as a detoxifying agent against various 
exogenous and endogenous toxins.
47
 Tiopronin 34 acts as a potent free radical scavenger
45
 
and that is why it is used as a very effective treatment of cystinuria.  
 
Cystinuria is an autosomal recessive genetic defect, which results in a breakdown of the 
transepithelial transport of cysteine in the kidney. This causes a build up of cysteine in the 
urine and once a high concentration is reached, cysteine crystallises and forms stones in the 
kidneys. Tiopronin 34 transforms cysteine into a mixed disulfide, 50 times more soluble 
than cysteine itself allowing it to be excreted with urine.
40 
 
Severe adverse reactions to oral thiol-drugs have been described in patients which include 
ageusia or dysgeusia rash, pemphigus, thrombocytopenia, myasthenia gravis, 
agranulocytosis, polymyositis, proteinuria, or hypersensitivity nephritic syndrome.
40,48,49
 
Tiopronin 34 is a racemate and each enantiomer was found to have different 
pharmacological and therapeutic effects. Selected preclinical pharmacological studies 
showed that (R)-Tiopronin (R)-34 had a much greater therapeutic effect on 
perchlormethane-induced acute liver injury in rats than the (S)-enantiomer.
50
 Currently, 
patients on Tiopronin 34 are recommended to have their peripheral blood count, direct 
platelet count, liver functioning tests as well as a whole list of other examinations to be 
done if they display any of the side effects.
51
 The analysis of each enantiomer of Tiopronin 
34 on a pharmacological basis will allow absolute confirmation whether the (R)-
enantiomer (R)-34 does have a greater therapeutic effect but also in the same instance it 
may be possible to eliminate some of the adverse reactions to the drug.  
 
Although the Tiopronin 34 racemate is commercially available from several sources in 
China, the single enantiomers are not widely available. Currently there are a few 
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asymmetric syntheses of (S)-Tiopronin (S)-34, requiring five steps and ten stages
52
 but 
there are even less reported syntheses for (R)-Tiopronin (R)-34.  
 
There are various methods for the synthesis of optically active thiols by nucleophilic 
substitution but they are racemisation prone
53-60
 and often restricted to certain substrates. A 
synthesis by nucleophilic substitution using caesium thiocarboxylates was reported
61
 with 
high yields and moderate to good enantiomeric excess (70–98%, 47–>98% e.e.).  
 
Alternatively, optically active thiols (R)-42 can theoretically be synthesised by 
nucleophilic substitution using optically active bromoacids (S)-35 (Scheme 1.10). 
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Scheme 1.10: Synthesis of (R)-Tiopronin (R)-34. 
 
 
1.3.4 Synthesis of other chiral starting materials from 2-bromoalkanoic acid 
 
In addition to therapeutic targets, chiral α-bromoacids can also be used to form other chiral 
starting materials such as α-hydroxy and α-amino groups (Scheme 1.11). The use of 
optically pure chiral starting materials at the beginning of a synthesis eliminates the need 
for resolution at the end and also eliminates the use of expensive chiral catalysts.  
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Scheme 1.11: Other chiral starting materials from 2-bromoalkanoic acid. 
Reagents and conditions: (i) NH3 in H2O
62
, (ii) caesium thiobenzoate, DMF
61
, (iii) NaH, THF, 
BnOCH2CH2OH
63
 or NaH, DMF, BnOCH2CH2OH
64
 (iv) NaOMe, MeOH, (v) PbOH, MeNH2, H2O, (vi) 
naphth-1-ol, NaOH, H2O, EtOH; (vii) dil. KOH (aq.). 
 
1.3.5 2-Fluoropropionic acid 83 
 
The fluorine atom has a van der Waal radius of 1.35 Å comparable to that of the hydrogen 
atom which is 1.20Å.
13
 Fluorine is regularly used as an isostere for hydrogen in bioactive 
molecules because of the similarity in steric bulk.
65
 A carbon-fluorine bond is 14 kcal/mole 
stronger than a carbon-hydrogen bond and is able to resist metabolic transformations such 
as oxidative degradation.
66,67
 Fluorine‟s influence in a bioactive molecule can affect any of 
a number of parameters, such as transportation of the bioactive molecule to the target site 
and binding to a target receptor or enzyme. Fluorine is also able to mimic other functional 
groups. The carbon-fluorine bond length is comparable to a carbon-oxygen bond length, 
1.39 Å versus 1.43 Å and is also a hydrogen bond acceptor and can be used to replace 
hydroxyl groups.
13
 Fluorine is also the most electronegative atom and incorporating it into 
bioactive molecules can have profound effects on the overall properties including electron 
density, basicity and acidity of neighbouring groups.
13
 Molecular recognition relies on 
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factors such as steric hindrance, electronegativity, dipole interactions and lipophilicity and 
fluorine is able to influence all of these aspects.
13
 The importance of chirality in 
pharmaceutical and agrochemical compounds indicates the need to synthesise 
enantiomerically pure fluorinated compounds.  
 
1.4 Chemical synthesis of α-haloacids  
 
1.4.1 Chemical synthesis of 2-bromopropionic acid 35 
 
Currently the industrial bromination reagents are molecular bromine 56 or hydrogen 
bromide 53. Synthesis of alkyl bromides 54 and α-bromoacids and esters 57 are conducted 
on a scale of kilograms to hundreds of tonnes with yields in the range 80-95% (Scheme 
1.12 and 1.13).
68 
 
R OH R BrHBr
R = alkyl
52 53 54  
 
Scheme 1.12: Synthesis of alkyl bromides 54 using hydrogen bromide 53.
68
 
Reagents and conditions: Reflux. 
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Scheme 1.13: Synthesis of α-bromoesters 57 using molecular bromine 56.68 
Reagents and conditions: ROH, 50-110 °C depending on the alcohol. 
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1.4.2 Chemical synthesis of enantiopure 2-bromopropionic acid 35 
 
Asymmetric bromination of acid chloride 58 has resulted in α-bromoester (S)-64 with high 
enantiomeric excess but this was not conveyable upon scale up (Scheme 1.14).
69
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Scheme 1.14: Asymmetric bromination of acid chlorides.
69 
Reagents and conditions: Cat. Nu, 15-crown-5, NaH, THF, LG – Br, -78 °C,5 h.  
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1.4.3 Chemical synthesis of 2-fluoropropionic acid 83 
 
Currently there are several methods for the synthesis of fluorinated compounds and these 
include nucleophilic fluorination and electrophilic fluorination, but methodology for 
asymmetric fluorination is not common and generally involves reagent controlled selective 
fluorinations.
13
 Additionally singularly fluorinated compounds are very difficult to 
synthesise due to the high reactivity of fluorinating reagents and this is reflected in the 
commercial availability and value of singularly fluorinated compounds compared to 
multifluorinated compounds. The starting material 2-fluoropropionic acid 83 is sold by 
Fluorochem Ltd. for £85/g.
70 
 
1.4.3.1 Nucleophilic fluorination 
 
Nucleophilic fluorinating reagents can be covalent or ionic in nature. Covalent nucleophilic 
fluorinating reagents such as diethylaminosulfur trifluoride 65 (DAST) generate fluoride in 
situ and reaction with alcohol 66 generates the reactive species 68, an 
alkoxydiethylaminosulfur difluoride intermediate. The fluoride that is generated attacks the 
intermediate 68 to afford the alkyl fluoride 70 (Scheme 1.15).
71-73
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Scheme 1.15: DAST mechanism.
71-73 
Reagents and conditions:  CH2Cl2, -50 – -78 °C. 
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Ionic nucleophilic fluorinating agents include silver fluoride, potassium fluoride and 
hydrogen fluoride. Silver fluoride has been used to fluorinate methyl-α-bromoisobutyrate 
71 to afford methyl-α-fluoroisobutyrate 72 (Scheme 1.16).74 
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Scheme 1.16: Fluorination of methyl-α-bromoisobutyrate 71 with silver fluoride.74 
Reagents and conditions: 140-145 °C, 3h. 
 
Although hydrogen fluoride is highly toxic, it has often been used as a fluorinating reagent. 
Its use as a fluorinating agent, however, is limited by its low boiling point (19.6 °C), which 
requires reactions to be conducted under pressure. Pyridinium poly-(hydrogen fluoride), 
synthesised from pyridine and hydrogen fluoride, is a less volatile fluorinating reagent and 
allows reactions to be conducted at atmospheric pressure. Many substrates have been 
fluorinated with this complex including α-amino acids 73, aminoarenes and carbamates to 
yield 2-fluorocarboxylic acids 75, fluoroarenes and fluoroformates respectively (Scheme 
1.17).
75 
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Scheme 1.17: Fluorination of α-amino acids 73 with pyridinium poly(hydrogen fluoride).75 
Reagents and conditions: pyridine, anhydrous HF, NaNO2, rt, 4 h. 
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1.4.3.2 Electrophilic fluorination 
 
Elemental fluorine can be considered as an electrophilic fluorinating agent and it has been 
used to fluorinate L-cysteine 76 to afford L-3-fluoroalanine 77 as the major product, with a 
yield of 33%, and L-3,3-difluoroalanine 78 as a minor product. Multifluorinations arise due 
to the high reactivity of elemental fluorine (Scheme 1.18).
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Scheme 1.18: Fluorination of L-cysteine (S)-76 using highly reactive elemental fluorine. 
Reagents and conditions: (i) -78 °C, HF, HBF4, (ii) 0 °C, F2/He (1:4 v/v), 3 h. 
 
Elemental fluorine is diluted in nitrogen and has been used to fluorinate silyl enol ethers in 
FCCl3 at -78 °C to afford α-fluoro ketones, α-fluoro aldehydes and α-fluoro carboxylic 
acids. Difluoro compounds were also formed and efforts to minimise this were 
unsuccessful.
77-79 
 
Other electrophilic fluorinating reagents have arisen in the last decade, which are more 
selective and don‟t result in multifluorination, including fluoroxy-trifluoromethane, an RO-
F reagent
80
, and Selectfluor
®
 79
81
, a N-F reagent (Figure 1.7). 
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Figure 1.7: Selectfluor
®
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81 
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1.4.4 Chemical synthesis of enantiopure 2-fluoropropionic acid 83 
 
Generally, asymmetric fluorinations involve chiral starting materials. Methyl-(S)-lactate 
(S)-80 was used to synthesise methyl (S)-2-methanesulfonyloxypropanoate (S)-81 with 
retention of stereochemistry. Fluoridation with potassium fluoride in formamide results in 
inversion of stereochemistry to afford (R)-2-fluorocarboxylic ester (R)-82, which was 
hydrolysed to the (R)-2-fluorocarboxylic acid (R)-83. Moderate to high yields (33-83%) 
and good to excellent enantioselectivity (55.5-98.7%) were reported for the synthesis of 
optically active 2-fluoropropionic acid (R)-83 and analogues (Scheme 1.19).
82
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Scheme 1.19: Asymmetric fluorination with chiral substrates.
82 
Reagents and conditions: (i) triethylamine, methanesulfonyl chloride, 4-N,N-dimethylaminopyridine, TBME, 
60 °C, 6 h, (ii) formamide, KF, 60 °C, 20 torr, 4 h, (iii) formic acid, distillation. 
 
1.5 Biocatalysis 
 
Biocatalysis is the use of enzymes as catalysts to perform chemical transformations on 
organic compounds. These transformations encompass the advantages associated with 
catalysts but with the selectivity of enzymes. There are numerous applications of 
biocatalysts reaching back to the oldest chemical transformations known to man, which 
include production of vinegar, fermentation of beer and wine and baking bread. 
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Biocatalysts are increasingly being used in a multitude of industries ranging from 
pharmaceutical, medicine and fine chemicals to food, energy production and mining. The 
use of biocatalysts is an environmentally friendly and cost effective option due to the mild 
conditions (low biotransformation temperatures, aqueous or biphasic solvents) they are 
used when compared to the energy demanding temperatures and pressures required for 
some chemical transformations. The use of biocatalysts allows the exploitation of their 
efficiency and selectivity. Under the mild conditions in which they are used, undesired side 
reactions such as rearrangements are minimised, which assist downstream purification.  
 
1.5.1 Biocatalysts 
 
Biocatalysts are able to catalyse reactions with high regio-, chemo- and stereospecificity 
and it is these properties of an enzyme that have attracted the attention of synthetic organic 
chemists.
14
 Although the substrate specificity of some biocatalysts is somewhat limited, 
when compared to conventional homogenous or heterogeneous catalysts, the ability of 
biocatalysts to differentiate between enantiomers of a substrate resulting in high yields and 
high enantioselectivities of >99% e.e. on a  routine basis have lead to their increasing use.  
 
1.5.2 Enzyme classes 
 
To categorise the immense number of enzymes, each enzyme has an identification number 
consisting of four numbers in the form EC A.B.C.D, where EC stands for „Enzyme 
Commission‟. Each letter codes for a property of the enzyme where A codes for the main 
type of reaction the enzyme catalyses, B codes for the subtype of reaction including 
information concerning the substrate, C codes for the nature of the co-substrate and D 
codes for the individual enzyme number (Table 1.1).
83
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Enzyme class Reaction type 
1 
Oxidoreductases 
Oxidation-reduction: oxygenation of C-H, C-C, C=C bonds, or overall 
removal or addition of hydrogen atom equivalents 
2 
Transferases 
Transfer of groups: aldehydic, ketonic, acyl, sugar, phosphoryl or 
methyl 
3 
Hydrolases 
Hydrolysis-formation of esters, amides, lactones, lactams, epoxides, 
nitriles, anhydrides, glycosides, organohalides 
4 
Lyases 
Addition-elimination of small molecules on C=C, C=N, C=O bonds 
5 
Isomerases 
Isomerisation such as racemisation, epimerisation, rearrangements 
6 
Ligases 
Formation-cleavage of C-O, C-S, C-N, C-C bonds with concomitant 
triphosphate cleavage 
 
Table 1.1: Classification of enzymes.
83 
 
1.5.3 Hydrolases (EC 3.X.X.X) 
 
Hydrolases are a large class of enzymes which include glycosylases, peptidases and 
esterases. Lipases (EC 3.1.1) are a sub-class of esterases which act on the ester bonds of 
carboxylic acids. Lipases in particular are ideal for industrial applications. Since they have 
evolved in nature to operate at an oil-water interface they have a propensity to be 
compatible with organic solvents. Also their broad substrate specificity results in their 
ability to catalyse a variety of reactions. Lipases are used in biocatalysis for kinetic 
resolutions, biofuel synthesis and organic synthesis. They are widely found in 
microorganisms, plants and mammals. Isolation of hydrolases from microbial sources is 
advantageous due to well-established production technologies on small and large scales. 
Many lipases are produced in vast quantities and at low costs and together with their wide 
applications, has resulted in hydrolases being the most widely used class of enzymes in 
industry.
84 
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1.6 Biosynthesis of halogenated compounds 
 
Halometabolites of marine organisms tend to incorporate the halogen bromine unlike 
terrestrial organisms, that have mainly chlorinated halometabolites. This is because there is 
a high bromine concentration in sea water.
85
 The enzymes that incorporate halogens into 
these metabolites are appealing as an alternative synthetic route to halogenated compounds. 
Research into this class of enzymes has revealed interesting results concerning their 
substrate specificity and regio- and stereoselectivity.  
 
There are currently five types of enzymes known to catalyse the formation of carbon-
halogen bonds: 
 
1. Haloperoxidases and perhydrolases 
2. Flavin dependent halogenases 
3. α-Ketoglutarate dependent halogenases 
4. Fluorinase 
5. Methyl transferases 
 
1.6.1 Haloperoxidases and perhydrolases 
 
The haloperoxidases are further categorised into two types: those that contain a haem 
group (H type) and those that do not contain a haem iron prosthetic group (NH type).  
 
The most studied H type enzyme of the haloperoxidases is the chloroperoxidase from 
Caldariomyces fumago and its substrates have also been well documented. They include β-
keto acids
86, cyclic β-diketones87, steroids88-91, substituted phenols92, alkenes93, alkynes94, 
α,β-unsaturated carboxylic acids95 and heterocycles96. 
 
One of the first NH type enzymes that was isolated was a vanadium containing 
bromoperoxidase from Ascophyllum nodosum. Many vanadium containing haloperoxidases 
were isolated from other algae and also from lichen and fungi but not from bacteria. The 
vanadium containing bromoperoxidase was found to be non-substrate specific too.
97 
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The wide range of substrates that are suitable for halogenation with Caldariomyces fumago 
and Ascophyllum nodosum give indications about the mechanism of these enzymes. The 
haloperoxidases, both H type and NH type, employ hydrogen peroxide for peroxidation of 
chloride and bromide anions into halide cations. The halide is then transferred to the 
substrate in an electrophilic substitution mechanism.
98
 The halogenating species was later 
confirmed to be hypohalous acid. The halogenating species is released from the enzymes 
active site before halogenation occurs.
95
 This explains the wide range of substrates that the 
enzymes are able to catalyse and the non-stereoselectivity of the enzymes.
95
 The three 
dimensional structures of the haloperoxidases from Caldariomyces fumago and 
Ascophyllum nodosum supported the proposed mechanism. Both the H and NH types of 
haloperoxidase therefore catalyse the reaction in a mechanistically related manner and 
because the halogenation step is not enzyme catalysed, the overall process is non-regio- 
and non-stereospecific (Scheme 1.20).
95,97,99 
 
Enzymatic reaction:
H2O2 + X
- + H+ HOX + H2O
Haloperoxidase
Non-enzymatic reaction:
HOX + AH + H2OA X
X = Cl, Br or I  
 
Scheme 1.20: Haloperoxidase reaction.
97
 
 
One of the first perhydrolases isolated was by Wiesner et al. from Burkholderia pyrrocinia 
formerly known as Pseudomonas.
100
 This perhydrolase does not contain any metal ions or 
require a co-factor but still used hydrogen peroxide to generate the halogenating species, 
hence they were classed as haloperoxidases. As more of these perhydrolase enzymes were 
discovered, a comparison of their structures revealed an α,β-hydrolase fold.101 
Perhydrolases catalyse the formation of peracids which when released from the enzyme 
active site react with halide ions to form the corresponding hypohalous acid. Subsequent 
reaction of the hypohalous acid with the substrate is spontaneous resulting in no regio- or 
stereoselectivity in the reaction.
97
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1.6.2 Flavin dependent halogenases 
 
The discovery of new haloperoxidases and perhydrolases was facilitated by the use of the 
monochlorodimedone (MCD) assay developed by Hager et al.
87
 MCD is not a naturally 
occurring halometabolite and therefore may have little resemblance to the natural 
substrates of the enzymes responsible for stereoselective halogenation reactions in nature. 
  
To discover a new class of enzymes that were able to synthesise these naturally occurring 
halometabolites required a different approach. By cloning the gene cluster for the 
biosynthesis of 7-chlorotetracycline in Streptomyces aureofaciens, Dairi et al. were able to 
deduce the gene responsible for carbon-halogen bond formation.
102
 This approach was also 
used to identify the gene cluster responsible for the biosynthesis of pyrrolnitrin from 
tryptophan 84. Tryptophan 84 was used as a screen for halogenases within the gene cluster, 
as it was suggested that 7-chlorotryptophan 89 was the first intermediate species.
103,104
 
Two genes and their halogenating functions were identified: tryptophan-7-halogenase 
(PrnA) and monodechloroaminopyrrolnitrin-3-halogenase (PrnC).
104
 It was found that 
NADH or FADH2, FAD
+
, oxygen and a flavin reductase were needed for these enzymes to 
function.
105,106
 Both PrnA and PrnC were found to have a flavin-binding site.
102,103,106
 
 
It has been proposed that these enzymes generate hypohalous acid which is not released 
from the enzyme, unlike the haloperoxidases, leading to high selectivity. Instead the 
hypohalous acid travels along a “tunnel” lined with amino acid side chain residues to the 
tryptophan where it is activated by Lys79 (Scheme 1.21). The hypohalous acid is 
positioned spatially within the active site leading to high regioselectivity of the enzyme 
catalysed reaction.
107
 
 
Understanding the role of halogenases involved in the biosynthesis of halometabolites is a 
challenging problem, as is deducing the halogenating step. It has also been observed, 
whilst studying the halogenases responsible for the production of other halometabolites, 
that the free substrate is not always accepted by the enzymes. Instead the substrate may 
need to be bound to an acyl or to a peptidyl carrier protein.
108,109
 Few flavin dependent 
halogenases use free forms of their substrates, but a few examples include tryptophan, 
monodechloroaminopyrrolnitrin and 2-(3,5-dibromo)-phenylpyrrole.
110-112
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Scheme 1.21: Proposed regioselective reaction mechanism of flavin-dependant 
halogenases. 
 
1.6.3 Fluorinase 
 
The fluorinase is so named because it is a rare enzyme that catalyses formation of a 
carbon-fluorine bond. Sanada et al. noticed that Streptomyces cattleya produced 
fluoroacetic acid and 4-fluorothreonine.
113
 The substrate for fluorinase is (S)-adenosyl-L-
methionine 90 and L-methionine is replaced by fluoride to make 5'-fluoro-5'-
deoxyadenosine 91, which undergoes metabolism to 4-fluorothreonine 92 and 
fluoroacetate 93 (Scheme 1.22).
75
 Fluorinase has been found recently to also be a 
chlorinase.
114
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Scheme 1.22: Fluorination of (S)-adenosyl-L-methionine 90 by Fluorinase. 
 
The use of halogenases to synthesise carbon-halogen bonds in a preparative manner would 
represent a major accomplishment. Both haloperoxidases and perhydrolases display no 
regioselectivity or stereoselectivity since the halogenating species is free hypohalous acid. 
The flavin-dependent halogenases are difficult to work with due to the bound substrates. 
The substrate specificity of the fluorinase enzyme is currently limited. However, novel 
halogenated metabolites have been synthesised from flavin-dependent halogenases
115
 and 
the future of using halogenases in mainstream chemistry shows potential. 
 
1.7 Kinetic resolution of α-haloacids and esters using lipases 
 
Resolution of α-haloacids and -esters using enzymatic methods allows for the high regio-, 
chemo- and stereoselectivity associated with enzymes. Kinetic resolution also affords both 
enantiomers of the α-haloacids/esters, which enables the synthesis of target molecules of 
both enantiomeric series thereby avoiding wasting 50% of the starting material. 
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1.7.1 Kinetic resolution of α-haloacids 
 
Kinetic resolution of α-haloacids rac-94 allows the separation of the enantiomers via 
enzymatic conversion of one of the enantiomers to the ester (R)-95, which can be 
hydrolysed back to the acid (R)-94 (Scheme 1.23).  
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Scheme 1.23: Kinetic resolution of racemic α-haloacids rac-94 leads to enantiopure α-
haloacids (S)-94 and (R)-94 via the ester (R)-95. 
 
Several lipases including Candida rugosa, formally known as Candida cylindracea, lipase 
and porcine pancreatic lipase (PPL), have been reported to be active towards α-haloacids 
as substrates in organic solvents. Both of these lipases are commercially available, require 
no co-factor for activity and have broad substrate specificity. The reactions were conducted 
in hexane and although the lipases were insoluble, Candida rugosa retained activity whilst 
PPL had low activity. High enantiomeric excesses were achieved when racemic acids were 
esterified with an excess of n-butyl alcohol using Candida rugosa and the lipase was (R)-
selective. The substrate specificity was investigated and results showed that an electron 
withdrawing group on the acid was necessary for activity.
116
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1.7.2 Kinetic resolution of α-haloesters 
 
Another route to enantiomerically pure α-haloacids (R)- and (S)-94 is via hydrolysis of α-
haloesters rac-96 (Scheme 1.24).  
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Scheme 1.24: Kinetic resolution of racemic α-haloesters rac-96 to enantiopure α-haloacids 
(R)- and (S)-94. 
 
In this study, more hydrolases were identified as being active towards α-haloesters in 
aqueous buffer than towards α-haloacids in organic solvents. Several hydrolases have been 
reported as having activity in the kinetic resolution of α-haloesters including Carlsberg‟s 
subtilisin, Bacillus subtilis and Pseudomonas fluorescens. Both Bacillus subtilis and 
Pseudomonas fluorescens lipase have shown stereoselectivity towards (S)-α-haloesters 
with varying  enantiomeric excesses depending on the substrate used (Scheme 1.24 and 
Table 1.2).
117,118
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Biocatalyst 
Substrate Conversion 
% 
e.e. of (R)  
ester % 
e.e. of (S) 
acid % X R 
Bacillus subtilis
a 
 
Br 
 
Me 
 
22 
 
- 
 
89
b 
 
Bacillus subtilis
a 
 
Br 
 
Et 
 
33 
 
- 
 
5
b 
 
Bacillus subtilis
a 
 
Br 
 
Bu 
 
34 
 
- 
 
8
b 
 
Pseudomonas fluorescens 
 
F 
 
Et 
 
50
c 
 
84
d 
 
- 
 
Pseudomonas fluorescens 
 
F 
 
Et 
 
60
c 
 
99.9
d 
 
68.5
d 
 
Pseudomonas fluorescens 
 
Br 
 
Me 
 
60
c 
 
93.5
d 
 
93
d 
 
Pseudomonas fluorescens 
 
Br 
 
n-Bu 
 
50
c 
 
72
d 
 
- 
 
Pseudomonas fluorescens 
 
Br 
 
Et 
 
50
c 
 
72.5
d 
 
69.4
d 
 
a
 wet whole cells as enzyme, 
b
 e.e. % determined by optical rotation values,  
c
 % conversion determined by the amount of base added, 
d
 e.e. % determined by GC of the 
diastereomeric Mosher‟s ester derivatives, - indicates data not given.  
 
Table 1.2: Kinetic resolution of α-haloesters using whole-cells and isolated enzymes.117,118 
Reagents and conditions: (a) Bacillus subtilis, phosphate buffer, pH 8.0, 25 °C, 4 h, (b) Pseudomonas 
fluorescens, buffer, pH 6.5, 30 °C. 
 
1.8 Directed Evolution 
 
Many enzymes have evolved to catalyse specific reactions in certain biochemical pathways. 
To fine tune the properties of an enzyme to a different application requires alteration and 
optimisation of the enzyme activity. This can be done by medium engineering, 
immobilisation of the enzyme or even change of reaction conditions. One example showed 
that upon addition of Tween-80 to a Candida antarctica lipase B (Cal B) catalysed kinetic 
resolution of N-(2-ethyl-6-methylphenyl) alanine methyl ester, the enantioselectivity 
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increased from 11.3 to 60.1.
119,120
 A complimentary approach to changing enzyme activity 
is by protein engineering. This method potentially allows changes in substrate specificity, 
catalytic activity, solubility and even enhancement of regio-, chemo- or stereospecificity. 
Evolutionary techniques are required to evolve the gene that codes for the enzyme.
121,122
 
Directed evolution involves mutations to the gene, expression of the mutant enzymes and a 
high throughput screening method for the desired characteristic. The mutant that possesses 
the desired improvement is selected and then subjected to further rounds of evolution until 
the required level of improvement is achieved (Figure 1.8).  
 
 
Figure 1.8: Schematic representation of the directed evolution process.
121 
 
Currently, there are several ways to generate libraries of variant genes in the laboratory, 
including error-prone polymerase chain reaction (epPCR)
123-125
, DNA shuffling
126,127
 and 
iterative saturation mutagenesis (ISM).
128
  
 
Once a library has been generated, consisting of thousands of variants, screening allows for 
the identification and isolation of positive clones. Screening is generally seen to be the 
bottleneck in the process of directed evolution since each variant requires expression 
before screening. The ideal assay would allow rapid and reliable determination of the 
Directed  
Evolution 
1. Select gene 
 
2. Create library of 
variants 
3. Insert gene library 
into expression vector 
4. Insert gene library/ vector into 
bacteria, which produce enzyme 
variants 
5. Screen colonies for the 
property of interest 
6. Isolate improved gene 
and repeat the process 
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property of an enzyme with high accuracy and reproducibility. Additionally, an assay 
should convey true information about enzyme kinetics, activities and selectivities.  
 
1.8.1 Mutagenesis techniques 
 
1.8.1.1 Error prone PCR (epPCR) 
 
The polymerase chain reaction is a technique to exponentially replicate DNA; however 
with epPCR the reliability of the genetic replication process is compromised in order to 
incorporate „errors‟. Thermus aquaticus (Taq) DNA polymerase is the enzyme used to 
incorporate random nucleotide mutations, which result in amino acid substitutions. These 
mutations arise due to the lack of proof reading using the Taq DNA polymerase alone. 
Variation of the reaction conditions are also used to generate mutations including addition 
of Mn
2+
 as an additional co-factor, having a biased ratio of nucleotides and/or an increased 
concentration of nucleotides.
123-125
 The mutated genes are then re-cloned into an expression 
vector and then transformed into a suitable host, where the mutants can be screened for the 
desired characteristic.
129 
 
1.8.1.2 Iterative saturation mutagenesis (ISM) 
 
Iterative saturation mutagenesis is a recently developed method which minimises the 
screening effort required to locate the mutant with the desired characteristic. ISM involves 
initially the analysis of the protein structure for regions which may significantly affect the 
catalytic activity. Once these regions have been identified they are targeted for rounds of 
saturation mutagenesis. The amino acids in these regions or „hot spots‟ are substituted for 
all other 19 natural amino acids.
130,131
 If four regions of a protein are submitted to 
saturation mutagenesis, then the best hit from each of those libraries is used as a template 
for the next round of saturation mutagenesis (Figure 1.9).
128
  
 
 44 
A
A
A A
AA
A
A
ABB
B
BB
B
B
BB
C
CC
CC
C
CC
C
DD
D
DD
D
D
D
D
A AA BBB CC DD DC A BCD
wild type enzyme
etc.
 
 
Figure 1.9: Iterative saturation mutagenesis.
128 
 
Furthermore not all pathways need to be explored. For instance, if library A has the best hit 
after the first round of saturation mutagenesis then this library can be focussed on. The 
other libraries can be reviewed once options in library A have been exhausted.
128
 
 
1.8.2 Screening 
 
There are several high throughput screening methods that are used in laboratories including 
colorimetric/ fluorometric assays or chromatographic assays. The chromatographic assay is 
the least high throughput as preparation of samples for common analytical techniques such 
as gas chromatography are required. The most commonly used screens are colorimetric/ 
fluorometric screens, where even small fluctuations in activity can be observed. Also this 
screen is a high throughput method with samples being screened in microtiterplates 
simultaneously.
132,133
  
 
1.8.2.1 Solid phase tributyrin agar screen 
 
The tributrin agar screen is a preliminary screen used to identify mutants of hydrolytic 
enzymes that are not able to hydrolyse the substrate tributyrin.
134
 Tributyrin is insoluble when 
added to agar and the agar takes on a milky appearance (Figure 1.10).  
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Figure 1.10: Left – Opaque tributyrin agar plates  
Right – Transparent agar plates. 
 
The products from hydrolysis of tributyrin are soluble and so in the case of an active 
mutant, clear spots appear around the mutant colony (Figure 1.11). 
 
 
 
Figure 1.11: Right – Tributyrin agar test of an active lipase with a clear halo surrounding 
the colonies  
Left – An inactive mutant showing no hydrolysis of the tributyrin substrate. 
 
The active mutants highlighted by the clearance halos can be picked for further 
investigation thereby reducing the number of mutants that need to be grown in liquid phase 
for further analysis.  
 
1.8.2.2 para-Nitrophenyl acetate screen (pNPA) 
 
The para-nitrophenyl acetate assay is a high throughput assay, that can be used to 
determine the activity of hydrolytic enzymes.
135
 The pNPA assay makes use of a 
chromogenic substrate,  para-nitrophenyl acetate 97 and represents a facile and 
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quantitative method to monitor hydrolytic reactions, because for every mole of substrate 
hydrolysed, one mole of para-nitrophenol 98 is formed (Scheme 1.25). 
  
O2N
OH OH
O
O2N
O
O
Lipase
97 98 99
 
 
Scheme 1.25: pNPA assay reaction. 
 
The product, para-nitrophenol 98, is colourless when protonated, but becomes yellow in 
aqueous alkaline solutions and hence can be detected at 410 nm allowing directed 
measurement of enzyme activity. The assay can be conducted in 96-well plates allowing 
for high throughput screening of libraries of variants. The screen takes only a few minutes 
to conduct and together with multichannel pipettes permits the screening of hundreds to 
thousands of mutants a day. However, a disadvantage of the pNPA assay is the use of a 
surrogate substrate. This assay is mostly used to further reduce screening efforts by 
eliminating inactive mutants. 
 
1.8.2.3 High throughput enantioselective screen 
 
To date, very few high throughput enantioselective screens have been reported. The first 
such screen was described by Reetz et al., in 1997
134
 and is based on an adaptation of the 
pNPA assay.
136
 In place of using a racemic chromogenic substrate, which would only give 
kinetic information about the mutants, the rate of hydrolysis of enantiopure substrates, 
tested in separate wells, is measured to assess the enantioselectivity. Comparison of the 
rate of reaction for each enantiomer shows the apparent enantioselectivities of the mutants. 
True enantioselectivities then need to be calculated by using more conventional chiral 
analytical techniques. 
 
1.9 Candida antarctica lipase B (Cal B) 
 
Cal B is a well known lipase used in industry and has been the subject of a large amount of 
research in academia. There are numerous publications dealing with Cal B showing that it 
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is an efficient enzyme with applications in regio- and enantioselective synthesis. Cal B is 
highly robust and although its optimal pH for catalysis is 7, it can operate in a pH range of 
3.5–9.5 and in organic solvents. Its high denaturation temperature and the fact that it can be 
easily immobilised, which further increases thermostability
137,138
, has allowed it to find its 
way into many industrial applications.  
 
1.9.1 Cal B structure and mechanism of hydrolysis of an ester 
 
The X-ray crystallographic structure of Cal B was solved in 1994 by Uppenburg et al.
139,140
 
allowing prediction of selectivity and providing an additional tool for molecular modelling 
studies. Cal B is 317 amino acids in length and possesses an α/β- hydrolase fold.141 A 
characteristic of lipases is the catalytic triad at the active site. Cal B has a catalytic active 
site consisting of the residues serine 105 (Ser105), aspartic acid 187 (Asp187) and histidine 
224 (His224). The active site is situated at the bottom of a narrow and deep hydrophobic 
tunnel approximately 10 x 4 Å wide and 12 Å deep.
140,142
 The active site consists of two 
channels; one which accommodates the acyl moiety and the other the alcohol moiety of an 
ester substrate.
142
 
 
The substrate ethyl butyrate 100 is hydrolysed to butanoic acid 105 by Cal B. The 
mechanism involves the binding of the substrate 100 to the active site of Cal B. The 
oxygen of the hydroxyl side chain on the Ser105 residue is positioned to be the catalytic 
nucleophile. The hydroxyl group attacks the carbonyl carbon of the ester substrate 100. 
The His224 residue acts as a hydrogen acceptor and accepts a proton from Ser105 (A, 
Scheme 1.26). An electron pair moves from the carbonyl bond onto the oxygen to form a 
tetrahedral intermediate. The oxyanion intermediate is stabilised by a hydrogen bonding 
network composed of the residues Thr40 and Gln106. The negative oxygen reforms the 
carbonyl bond and the carbon-oxygen bond of the alcohol moiety is broken, with His224 
now acting as a hydrogen donor (B, Scheme 1.26). The ethanol that is produced is released 
from the active site and water enters to re-establish the active site. The water molecule is 
activated by His224 and acts as a nucleophile to attack the carbonyl of the acyl-enzyme 
intermediate (C, Scheme 1.26). The newly generated negative oxygen reforms the carbonyl 
bond and breaks the C–O bond between the substrate and the enzyme which accepts a 
proton from His224 (D, Scheme 1.26). The product, butanoic acid 105, is released from the 
active site and the active site is reinstated for further catalysis (E, Scheme 1.26). The 
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Asp187 catalytic triad residue serves to stabilise the changing nature of His224 via 
hydrogen bonding with the carbonyl group in Asp187 (Scheme 1.26). 
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Scheme 1.26: Ester hydrolysis mechanism by Cal B. 
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1.9.2 Biosynthesis of biodiesel using Cal B 
 
Cal B has many industrial applications including the biosynthesis of biodiesel. Biodiesel, 
which is an alternative to conventional fossil fuel based diesel, can be prepared from 
locally generated waste products such as spent cooking oil and animal fats and a catalyst 
such as Cal B.
143,144
 The use of biocatalysts are advantageous over traditional chemical 
alcoholysis as the enzymatic route tolerates more diverse feedstock, conserves energy and 
has minimised side reactions, which alleviates downstream purification. The blend of 
triglycerides and fatty acids undergo transesterification and esterification with short chain 
alcohols to fatty acid alkyl esters to be used in conventional diesel engines. Cal B used in 
conjunction with lypozyme is the first reported lipase catalysed biodiesel production on an 
industrial scale worldwide. In China this technology is used to produce 20,000 tons per 
year of biodiesel.
145
  
 
1.9.3 Enantioselective synthesis of (+)-harzia lactone A, 56 using Cal B 
 
Cal B has been applied to the enantioselective synthesis of (+)-harzia lactone A 106. Many 
natural products, such as (+)-harzia lactone A 106, have been found to harbour a wealth of 
new pharmacological properties. The problem arises when attempting to discover which 
enantiomer is the active compound for large scale synthesis which requires access to both 
enantiomers of (+)-harzia lactone A 106. Cal B was used for the synthesis of the secondary 
metabolite, (+)-harzia lactone A 106, which showed moderate biological activity against 
infective agents (Figure 1.12). 
 
O
OH
O
Ph
106
 
Figure 1.12: (+)-Harzia lactone A, 106. 
 
An investigation into whether the (–)-stereoisomer had increased levels of cytotoxicity 
over the (+)-stereoisomer was conducted. The absolute configuration of (+)-harzia lactone 
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A 106 was determined as (3R,5R)-106 by chemical synthesis from D-glucose
146
 and D-
xylose
147
, each in seven steps. To access the (–)-stereoisomer, a synthesis was undertaken 
from L-malic acid to give the (3S,5S)-enantiomer. A more simplified approach would be a 
kinetic resolution of an intermediate from which both stereoisomers can be obtained. Cal B 
was used for the kinetic resolution of homoallylic alcohol 107 to give selective acylation of 
the (R)-enantiomer (R)-107 with a yield of 47% and an enantiomeric excess of 97%. The 
(S)-enantiomer (S)-107 was recovered in 44% yield and an enantiomeric excess of 87%. 
From these chiral intermediates the first chemoenzymatic route to all stereoisomers of 
harzia lactone A was developed (Scheme 1.27).
148 
 
OH
OH
OAc
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87% e.e.
(R)-108
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Scheme 1.27: Kinetic resolution of homoallylic alcohol 107 using Cal B. 
Reagents and conditions: Cal B, vinyl acetate, α-iso-propyl ether, 25 °C, 26 h. 
 
1.9.4 Enhancing the enantioselectivity of Cal B towards secondary alcohols by 
directed evolution 
 
There are numerous reports of the use of Cal B to kinetically resolve secondary alcohols 
yielding enantiomerically pure products in high enantiomeric excess.
148
 Cal B is often 
included in screening processes due to its broad substrate specificity.  
 
Cal B was used for the kinetic resolution of secondary alcohols bearing keto or acetoxy 
groups in the δ-position from the carbinol.149 Cal B has a small enantiorecognition pocket 
for secondary alcohols defined by threonine 42 (Thr42), serine 47 (Ser47) and tryptophan 
104 (Trp104).
150-152
 Poor enantioselectivity (ER = 9) was initially reported for the kinetic 
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resolution of secondary alcohols bearing keto or acetoxy groups. The kinetic resolution of 
simpler secondary alcohols, such as those bearing a hydroxy group, using Cal B has been 
reported with an ER = >200. The difference in ER was attributed to the interaction of the δ-
position functional group with the surrounding active-site residues. Electrostatic 
interactions between the substrate and enzyme induced by a small polar environment close 
to the oxyanion hole created by threonine 40‟s carbonyl group was found to be especially 
important. The mutant Ala281Ser was designed to probe this model and was produced by 
site-directed mutagenesis. This variant was found to have a 13-fold higher 
enantioselectivity (ER = 120). This example demonstrates that the enantioselectivity of Cal 
B can be enhanced significantly by introducing a single amino acid change. 
 
1.9.5 Enhancing the enantioselectivity of Cal B by engineered substrate-assisted 
catalysis 
 
To enhance the enantioselectivity of lipases, strategies such as site-directed 
mutagenesis
153,154
 and directed evolution
155,156
 have been used. A complementary approach 
is to employ substrate engineering. The kinetic resolution of ethyl 2-hydroxypropanoate 
using Cal B proceeded with very poor enantioselectivity (ER = 1.6).
157
 It was proposed that 
the hydroxyl group of the substrate ethyl 2-hydroxypropanoate could substitute for an 
active site residue namely Thr40 (Figure 1.13). As discussed in the sections 1.91 and 1.9.4, 
the Thr40 residue is part of a network of hydrogen bonds that stabilises the intermediate. 
Specifically it is the hydroxyl side chain and the amide backbone of Thr40 that constitute 
two of the three hydrogen bonds in this network.
158
 The mutants Thr40Val and Thr40Ala 
were engineered using site directed mutagenesis. The kinetic parameters of these mutants 
were compared to the wild-type and it was found that the Thr40Val and Thr40Ala mutants 
had kcat/kM values three orders of magnitude lower than the wild-type. Screening of the 
mutants Thr40Val and Thr40Ala with the substrate ethyl 2-hydroxypropanoate showed an 
increase of enantioselectivity to 22 and 9.8 respectively. Through engineering of the 
enzyme or the substrate, it has been shown that properties such as enantioselectivity can be 
manipulated. 
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Figure 1.13: Cal B active site.  
A = transition-state stabilisation in wild-type enzyme. B = Substrate-assisted transition state stabilisation in a 
Thr40Val mutant. 
 
1.9.6 Enhancing the enantioselectivity of Cal B using a genetic selection system 
 
Section 1.8 discusses the combination of gene mutagenesis, expression and high 
throughput screening of libraries of enzyme variants. In place of screening, selection has 
also been reported in which cell survival is linked to an enzyme-catalysed reaction.
159-161
 
This selection strategy has been applied to the hydrolytic kinetic resolution of esters of 
chiral isopropylidine glycol 109.
162
 Cal B displays an ER of 1.9 for the kinetic resolution of 
racemic isopropylidene glycerol acetate 109 in which Cal B is (R)-selective. (S)-
isopropylidene glycerol acetate (S)-109 and (R)-isopropylidene glycerol fluoroacetate (R)-
112 were synthesised as pseudo-enantiomers for the selection strategy. Upon hydrolysis of 
(S)-isopropylidene glycerol acetate (S)-109, acetic acid 111 and (R)-isopropylidine glycol 
(R)-110 are formed. The expression host, Pichia pastoris, can use acetic acid 111 as a 
carbon source (Scheme 1.28). However, upon hydrolysis of (R)-isopropylidene glycerol 
fluoroacetate (R)-112 the product formed is fluoroacetic acid 113, which is toxic to the 
expression host (Scheme 1.29).  
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Scheme 1.28: Hydrolysis of (S)-isopropylidene glycerol acetate (S)-109 by Cal B to form 
acetic acid 111 and (R)-isopropylidine glycol (R)-110. 
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Scheme 1.29: Hydrolysis of (R)-isopropylidene glycerol acetate (R)-112 by Cal B to form 
acetic acid 113 and (S)-isopropylidine glycol (S)-110. 
 
Mutagenesis of Cal B using the Combinatorial Active-Site Saturation Test (CAST), which 
involves systematic saturation mutagenesis at relevant residues, was carried out. Variants 
of Cal B were generated and screened using the selection assay. Selection plates with 0.3% 
of (S)-109 and 0.003% of (R)-112 were used for the assay. Variants of Cal B with an ER of 
3-8 were isolated and they had a reversal of enantioselectivity to the wild-type.  
 
There are many uses of Cal B as demonstrated in the examples in section 1.9. Additionally 
the use of molecular dynamics and directed evolution together creates a very powerful tool 
for the rational design of mutants. Novel screening systems for enantioselectivity are also 
being developed and have been applied to Cal B. With these tools the activity and 
enantioselectivity of Cal B can be enhanced for many industrial applications. 
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2 Results and Discussion 
 
2.1 Objectives 
 
The overall objective was to develop a scaleable biocatalytic process to access 2-
bromopropionic acid 35, 2-fluoropropionic acid 83 and their esters in a single enantiomeric 
form with a high enantiomeric excess. Since kinetic resolution based upon the hydrolysis 
or esterification of an appropriate substrate would allow access to both enantiomers, 
kinetic resolution of racemic 2-bromopropionic acid 35, 2-fluoropropionic acid 83 and 
their ester derivatives using hydrolases was proposed. 
 
In order to develop a biocatalytic process, several key objectives need to be met: 
 
a) Identification of a suitable hydrolase that would furnish 2-bromopropionic acid 35, 
2-fluoropropionic acid 83 and their ester derivatives at high conversion rates with 
reasonable optical purity. 
b) Once a hydrolase had been identified, isolation of the gene and insertion into a 
suitable vector for production of soluble and active protein. 
c) Purification and characterisation of the protein to be used as a baseline for genetic 
manipulation. 
d) Development of a strategy to identify mutants of the hydrolase with enhanced 
enantioselectivity. 
 
This approach would allow the synthesis of both enantiomers of a small range of chiral 
starting materials and some pharmacologically active target compounds. 
 
2.2 Chiral analytical techniques 
 
In order to screen for active lipases against the substrates 2-bromopropionic acid 35 and 2-
fluoropropionic acid 83 (Table 2.1), a chiral high-performance liquid chromatography 
(HPLC) method was developed which allowed analysis of the biotransformation reactions. 
The separation of the enantiomers of the substrate (acid) and the product (ester) was 
achieved on a chiral Daicel Chiralpak
®
 AD-H column using an eluent combination. The 
separated substrate and product were then detected by UV. Using the developed HPLC 
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methods, retention times of the standards were recorded (Table 2.2) with assignment of the 
HPLC peaks being achieved by comparison with authentic samples. 
 
Substrate 
Column 
Temp. 
(°C) 
Flow rate 
(ml/ min) 
Mobile Phase 
Hexane 
% 
Ethanol 
% 
TFA 
% 
2-bromopropionic 
acid 35 
10 0.3 95 4.9 0.1 
2-fluoropropionic acid 
83 
22 0.3 95 4.9 0.1 
n-butyl-2-
bromopropionate 114
 
0 0.2 98 1.9 0.1 
Column – Daicel Chiralpak
®
 AD-H - 5 μm particle size, 4.6 mm internal diameter, 250 mm column length 
Table 2.1: Chiral HPLC conditions for the separation of 2-bromopropionic acid 35,  
2-fluoropropionic acid 83 and n-butyl-2-bromopropionate 114 using a Daicel Chiralpak
®
  
AD-H column. 
 
An HPLC method was developed to analyse the progress of the biotransformation 
reactions. This method allowed both the disappearance of the substrate, 2-bromopropionic 
acid 35 and the appearance of n-butyl-2-bromopropionate 114 from the esterification 
reaction of 2-bromopropionic acid 35 to be observed in a single analysis run. Chiral HPLC 
conditions with shorter retention times, providing baseline separation of the enantiomers of 
2-bromopropionic acid 35 and the appearance of n-butyl-2-bromopropionate 114, were 
also developed (Table 2.3 and Table 2.4). In the enzymatic esterification of 2-
fluoropropionic acid 83 only the disappearance of the substrate was monitored as the n-
butyl ester of 2-fluoropropionic acid 115 was not available.  
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Substrate Retention time (min) Assignment 
2-bromopropionic acid 
35  
28.7 
(S)-2-bromopropionic 
acid
1 
31.8 
 
(R)-2-bromopropionic 
acid 
 
2-fluoropropionic acid 83 
 
20.4 acrylic acid
1,2 
21.6 first acid enantiomer 
22.6 
 
second acid enantiomer 
 
n-butyl-2-
bromopropionoate 114 
23.7 first ester enantiomer 
24.3 second ester enantiomer 
1
 verified with authentic purchased samples, 
2
 product from degradation of substrate 
Table 2.2: Retention times of the authentic purchased standards using the method outlined 
in Table 2.1. 
 
Substrate 
Column 
Temp. (°C) 
Flow rate 
(ml/ min) 
Mobile Phase 
Hexane 
(%) 
Ethanol 
(%) 
TFA 
(%) 
2-bromopropionic 
acid 35 
 
40 1.5 95 4.9 0.1 
2-fluoropropionic 
acid 83  
40 1.0 95 4.9 0.1 
 
Table 2.3: HPLC conditions for the analysis of the biotransformation reactions on a Daicel 
Chiralpak
®
 AD-H column. 
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Substrate Retention time (min) Assignment 
2-bromopropionic acid 
35 
 
2.7 
n-butyl-2-
bromopropanoate
1 
5.0 
(S)-2-bromopropionic 
acid
1 
5.3 
 
(R)-2-bromopropionic 
acid
1 
 
2-fluoropropionic acid 83 
 
3.9 ester 
5.8 acrylic acid
1 
6.1 first acid enantiomer  
6.4 second acid enantiomer 
1
 verified with authentic purchased samples, 
2
 product from degradation of substrate 
Table 2.4: Retention times of the substrates and products of the biotransformation reactions 
using the method described in Table 2.3. 
 
The degree of conversion of the biotransformation reactions was measured by taking 
samples of the biotransformation reactions and analysing them using the HPLC method 
developed (Table 2.3). Samples of the substrate and product of known concentrations were 
also analysed using the HPLC method and the molar extinction coefficient (ε) was 
calculated. The degree of conversion was calculated using the ratio between the produced 
peak areas of n-butyl-2-bromopropanoate 114 (Aprod) and both enantiomers of 2-
bromopropionic acid 35 (Asub). This ratio is shown in Equation 1. The HPLC data was also 
used to calculate the enantiomeric excess of the substrate for the biotransformation 
reactions using Equation 2. The selectivity or enantiomeric ratio, ER, was calculated using 
conversion (c) and enantiomeric excess of the substrate (ee(S)) according to Chen et al. 
(Equation 3)
163
 
 
Conversion = (Aprod/ε) † ((Asub/ε) + (Aprod/ε)) (1) 
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ee =  conc. of the (S)-enantiomer – conc. of the (R)-enantiomer  (2) 
                    conc. of the (S)-enantiomer + conc. of the (R)-enantiomer 
 
ER = ln[(1–c)(1-ee(S))] ÷ ln[(1–c)(1+ee(S))]  (3) 
 
2.3 Screening of hydrolases for enantioselective esterification of α-bromo- and  
α-fluoropropionic acid 
 
A preliminary screen of a panel of hydrolases for the enantioselective esterification of the 
two substrates, 2-bromopropionic acid 35 and 2-fluoropropionic acid 83, with n-butanol 
117 was undertaken. A commercially available lipase kit from Alphamerix, Cambridge, 
UK containing 15 various lipases was used for the screening together with Candida rugosa 
esterase powder (Dr. Andrew Carnell, University of Liverpool, U.K.) which had been 
shown to be active in previous studies.
164
 The conditions chosen for the screening process 
were not optimised for a particular lipase and were the general conditions chosen for the 
initial screen. 
 
2.3.1 Screening of 2-bromopropionic acid 35 using a lipase kit 
 
The HPLC method developed for the analysis of the biotransformation reactions was used 
to monitor and analyse the reactions (Table 2.3). Samples were taken initially after 30 
minutes and 1 hour and they were analysed using the HPLC method described in Table 2.3. 
Based on those initial results, active enzymes were monitored more frequently (Table 2.5).  
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Scheme 2.1: Kinetic resolution of 2-bromopropionic acid 35 using a commercially 
available lipase kit. 
Reagents and conditions: 2-bromopropionic acid (0.5g/L), enzyme (0.5g/L), iso-hexane (2mL), 1-butanol (5 
equiv.), incubated in a 30 °C shaker. 
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Hydrolase 
Time 
(h) 
Degree of 
conversion 
(%)
2 
Acid 
35 ee 
(%)
3 
ER
4 
(R/ S) 
Concentration 
of protein 
μg/mL 
Species Preparation
1 
Pseudomonas 
cepacia lipase 
 
Alphamerix 
P1 AE 06 
 
48 
 
0 
 
- 
 
- 
 
134.9 
 
Alcaligenes 
spp lipase 
 
Alphamerix 
A1 AE 05 
 
48 
 
0 
 
- 
 
- 
 
28.5 
 
Achromobacter 
spp lipase 
 
Alphamerix 
AE 04 
 
48 
 
0 
 
- 
 
- 
 
37.9 
 
Candida 
cylindracea 
(rugosa) 
lipase 
 
Alphamerix 
C2 AE 02 
 
5 
6 
24 
 
56 
59 
59 
 
37 
38 
40 
 
2.5 (R) 
2.4 (R) 
2.5 (R) 
 
131.6 
Candida 
cylindracea 
(rugosa) 
lipase 
 
Alphamerix 
C1 AE 01 
 
24 
 
25 
 
11 
 
2.2 (R) 
 
64.3 
 
Pseudomonas 
cepacia lipase 
 
Alphamerix 
P2 AE 012 
 
48 
 
0 
 
- 
 
- 
 
56.8 
 
Alcaligenes 
spp lipase 
 
Alphamerix 
A2 AE 011 
 
48 
 
0 
 
- 
 
- 
 
194.3 
 
Aspergillus 
niger lipase 
 
Alphamerix 
AE 010 
 
48 
 
0 
 
- 
 
- 
 
97.9 
 
Rhizopus spp 
lipase 
Alphamerix 
AE 08 
48 
 
0 
 
- 
 
- 
 
210.2 
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Hydrolase 
Time 
(h) 
Degree of 
conversion
2
 
(%) 
Acid 
35 ee 
(%)
3 
ER
4
 
(R/S) 
Concentration 
of protein 
μg/mL 
Species Preparation
1 
Pseudomonas  
stutzeri lipase 
 
Alphamerix 
AE 07 
 
48 
 
0 
 
- 
 
- 
 
170.2 
 
 
Candida 
antarctica A 
lipase 
 
Alphamerix 
AE 0158 
 
24 
 
17 
 
5.2 
 
1.7 (R) 
 
287.4 
 
Mucor miehei 
lipase 
 
Alphamerix 
AE 0157 
 
5 
6 
 
67 
73 
 
32 
40 
 
1.8 (S) 
1.9 (S) 
 
66.3 
 
Candida 
antarctica B 
lipase 
 
Alphamerix 
AE 0156 
 
5 
6 
24 
 
51 
57 
100 
 
33 
37 
0 
 
2.6 (S) 
2.5 (S) 
1.0 
 
39.6 
 
Pseudomonas 
fluorescens 
lipase 
 
Alphamerix 
AE 078 
 
48 
 
0 
 
- 
 
- 
 
49.1 
 
Penicillium 
camembertii 
lipase 
 
Alphamerix 
AE 014 
 
48 
 
0 
 
- 
 
- 
 
16.0 
 
Candida 
rugosa 
esterase 
Altus 31 
5 
6 
24 
38 
43 
48 
13 
14 
17 
1.7 (R) 
1.7 (R) 
1.7 (R) 
29.9 
1
 Commercial supplier number
 2
 Calculated from HPLC data using Eq. 1 (Appendix 1). 
3
 Calculated from 
HPLC data using Eq. 2 (Appendix 2). 
4
 Calculated from HPLC data using Eq. 3 (Appendix 3). 
Table 2.5: Results from the kinetic resolution of 2-bromopropionic acid 35 using 
commercially available lipases.  
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The enzymes identified from this screen that were active towards 2-bromopropionic acid 
35 included both preparations of Candida cylindracea (rugosa), Candida antarctica A 
lipase, Mucor miehei lipase, Cal B and Candida rugosa esterase, however, the selectivity 
of these enzymes was not high. The most selective enzymes were Candida cylindracea 
(rugosa), the Alphamerix C2 AE 02 preparation, and Cal B with an ER of 2.4-2.5 and 2.5-
2.6 respectively. Very few enzymes were able to accept 2-bromopropionic acid 35 as a 
substrate in all probability due to the bulky bromine atom and the size of the active site in 
these enzymes. Interestingly Mucor miehei lipase and Cal B exhibited opposite 
stereopreference for the substrate 2-bromopropionic acid 35 to the other active enzymes. 
 
2.3.2 Screening of 2-fluoropropionic acid 83 using a lipase kit 
 
The lipase kit was also used to screen for activity against the substrate 2-fluoropropionic 
acid 83. The samples were analysed using the HPLC method outlined in Table 2.3. 
Samples were taken at regular intervals (Scheme 2.2 and Table 2.6).  
 
OH
O
F
On-Bu
O
F
OH
O
Frac-83 115 (R)-83  
 
Scheme 2.2: Kinetic resolution of 2-fluoropropionic acid 83 using a commercially 
available lipase kit. 
Reagents and conditions: 2-fluoropropionic acid (5g/L), enzyme (0.5g/L), iso-hexane (2mL), 1-butanol (5 
equiv.), incubated in a 30 °C shaker. 
 
When considering the steric hindrance caused by the bromine atom in 2-bromopropionic 
acid 35 in the active site of Cal B, in contrast to the comparatively small fluorine atom in 
2-fluoropropionic acid 83, one would expect more enzymes to be able to accept the 
substrate 2-fluoropropionic acid 83. However, the results show that fewer enzymes were 
able to process 2-fluoropropionic acid 83. Only two enzymes were found to be active 
towards 2-fluoropropionic acid 83, namely Alcaligenes spp lipase (Alphamerix A2 AE 011 
preparation) and Cal B. Once more the selectivity of these active enzymes was not high 
with ER values of 1.4 and 2.5 respectively. It was observed during HPLC method 
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development that 2-fluoropropionic acid 83 was not a stable substrate and liberated 
hydrogen fluoride to produce acrylic acid. Since the biotransformations were conducted in 
iso-hexane, with no buffering capacity available, it is possible that some of these reactions 
failed due to the highly acidic products from the degradation of the substrate. Cal B was 
able to process 2-fluoropropionic acid 83 because it can operate in a pH range of 3.5-9.5. 
Both active enzymes were selective for the first eluting enantiomer of 2-fluoropropionic 
acid 83. 
 
Hydrolase 
Time 
(h) 
Degree of 
conversion 
(%)
2 
Acid 
83 ee 
(%)
3 
ER
4 
(1/2) 
Concentration 
of protein 
μg/mL 
Species Preparation
1 
Pseudomonas 
cepacia lipase 
 
Alphamerix 
P1 AE 06 
 
48 
 
0 
 
- 
 
- 
 
134.9 
 
Alcaligenes 
spp lipase 
 
Alphamerix 
A1 AE 05 
 
48 
 
0 
 
- 
 
- 
 
28.5 
 
Achromobacter 
spp lipase 
 
Alphamerix 
AE 04 
 
48 
 
0 
 
- 
 
- 
 
37.9 
 
Candida 
cylindracea 
(rugosa) 
lipase 
 
Alphamerix 
C2 AE 02 
 
48 
 
0 
 
- 
 
- 
 
131.6 
 
Candida 
cylindracea 
(rugosa) 
lipase 
 
Alphamerix 
C1 AE 01 
 
48 
 
0 
 
- 
 
- 
 
64.3 
 
Pseudomonas 
cepacia lipase 
Alphamerix 
P2 AE 012 
48 0 - - 56.8 
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Hydrolase 
Time 
(h) 
Degree of 
conversion 
(%)
2 
Acid 
87 ee 
(%)
3 
ER
4
 
(1/2) 
Concentration 
of protein 
μg/mL 
Species Preparation
1 
Alcaligenes 
spp lipase 
 
Alphamerix 
A2 AE 011 
 
4 
 
33 
 
7 
 
1.4 (1) 
 
194.3 
 
Aspergillus 
niger lipase 
 
Alphamerix 
AE 010 
 
48 
 
0 
 
- 
 
- 
 
97.9 
 
Rhizopus spp 
lipase 
 
Alphamerix 
AE 08 
 
48 
 
0 
 
- 
 
- 
 
210.2 
 
Pseudomonas  
stutzeri lipase 
 
Alphamerix 
AE 07 
 
48 
 
0 
 
- 
 
- 
 
170.2 
 
 
Candida 
antarctica A 
lipase 
 
Alphamerix 
AE 0158 
 
48 
 
0 
 
- 
 
- 
 
287.4 
 
 
Mucor miehei 
lipase 
 
Alphamerix 
AE 0157 
 
48 
 
0 
 
- 
 
- 
 
66.3 
 
Candida 
antarctica B 
lipase 
 
Alphamerix 
AE 0156 
 
2 
24 
 
50 
100 
 
30 
0 
 
2.5 (S) 
1.0 
 
39.6 
 
Pseudomonas 
fluorescens 
lipase 
 
Alphamerix 
AE 078 
 
48 
 
0 
 
- 
 
- 
 
49.1 
 
Penicillium 
camembertii 
lipase 
Alphamerix 
AE 014 
48 0 - - 16.0 
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Hydrolase 
Time 
(h) 
Degree of 
conversion 
(%)
2 
Acid 
83 ee 
(%)
3 
ER
4
 
(1/2) 
Concentration 
of protein 
μg/mL 
Species Preparation
1 
Candida 
rugosa 
esterase 
Altus 31 
 
48 
 
0 
 
- 
 
- 
 
29.9 
 
1 
 Commercial supplier number 
2
 Calculated from HPLC data using Eq. 4 (Appendix 4). 
3
 Calculated from 
HPLC data using Eq. 2 (Appendix 2). 
4
 Calculated from HPLC data using Eq. 3 (Appendix 3). 
Table 2.6: Results from the kinetic resolution of 2-fluoropropionic 83 acid using lipases. 
 
2.3.3 Bicinchoninic acid assay 
 
To provide an indication of how much protein was present in each biotransformation, the 
total amount of protein was determined using a bicinchoninic acid (BCA) protein assay. It 
should be noted that the preparations of enzyme used were not pure. The assay works by 
combining the biuret reaction with colorimetric detection of the cuprous cation produced. 
In the biuret reaction, Cu
2+
 is reduced to Cu
1+
 by the protein in an alkaline medium and 
then the Cu
1+
 cation is detected by chelating with two molecules of BCA 116 (Scheme 
2.3).
165 
 
By preparing known concentrations of bovine serum albumin (BSA), the concentrations of 
protein in the biotransformations were determined. A standard curve, generated by plotting 
the average blank-corrected measurements for each BSA standard against concentration 
(µg/mL), was used to determine the protein concentration of each of the unknown samples. 
The BCA assay was conducted on a microplate scale and the end-point was measured at 
584 nm on a plate reader.  
 
 65 
Protein Cu2+ Cu
+1
OH
Cu+1 2BCA
N
N
Cu
N
N
-OOC COO
-
-OOC COO-
116
 
 
Scheme 2.3: Reaction schematic for the BCA assay.
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The enzymes that were active towards the substrate 2-bromopropionic acid 35 were 
Candida cylindracea (rugosa) Alphamerix C2 AE 02 preparation (131.6 µg/mL), Candida 
cylindracea (rugosa) Alphamerix C1 AE 01 preparation (64.3 µg/mL), Candida antarctica 
A lipase (287.4 µg/mL), Mucor miehei lipase (66.3 µg/mL), Cal B (39.6 µg/mL) and 
Candida rugosa esterase (29.9 µg/mL). The enzymes that were active towards the 
substrate 2-fluoropropionic acid 83 were Alcaligenes spp lipase Alphamerix A2 AE 011 
preparation (194.3 µg/mL) and Cal B (39.6 µg/mL). There was no correlation between the 
amount of protein present in the biotransformations and the activity of the enzymes 
towards the substrates. The Cal B lipase, which was found to be active towards both 2-
bromopropionic acid 35 and 2-fluoropropionic acid 83, had a very low protein 
concentration when compared to some of the other preparations. 
 
2.3.4 Results of the initial screen of hydrolase enzymes 
 
Enantioselectivity arises from a difference in rates of reaction of one enantiomer over the 
other, which is in turn derived from the difference in activation energies and this difference 
is due to the way each enantiomer fits into the active site. Chiral discrimination occurs 
when one enantiomer fits into the active site preferentially over the other. As the initial 
screen showed, none of the enzymes tested was truly enantioselective and the enzymes 
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were able to accept both enantiomers. Highly enantioselective enzymes reach a conversion 
of ca. 50 % whilst enzymes with low enantioselectivity are able to proceed to 100 % 
conversion. This is because after one enantiomer has been converted, it will proceed to 
react with the slower enantiomer resulting in a racemic mixture of the product. As Cal B 
demonstrated activity towards both 2-bromopropionic acid 35 and 2-fluoropropionic acid 
83, it was decided to select this lipase for further study, particularly the application of 
protein engineering methods to improve the ER of the reaction. 
 
2.4 Cloning of the Cal B gene for protein production 
 
The next phase of the project involved the development of a suitable expression system for 
the over-production of soluble and active Cal B. Prior to 2006, the production of Cal B was 
prepared in Aspergillus oryzae, for large scale industrial purposes
166
, and in Pichia pastoris 
(P. pastoris)
167
 and Saccharomyces cerevisiae, for research applications
168
. The first 
functional expression of Cal B in the cytoplasm of Escherichia coli (E. coli) was in 2006 
by Liu et al.
169
 The expression of Cal B from several different plasmids and strains of E. 
coli was reported. The expression system in which Cal B was most efficiently expressed 
was from a pColdIII construct with coexpression of pGro7, a molecular chaperone (61 U 
mg
-1
).  
 
The Cal B gene in a pPIC9 vector for expression in P. pastoris was kindly provided by 
Professor Stefan Lutz (Emory University, U.S.A.) (Figure 2.1). 
 
Eukaryotic systems allow secretion of the protein into the medium, which facilitates 
subsequent purification. Eukaryotic systems are also capable of post-translational 
modifications such as glycosylation and disulfide bond formation, which results in higher 
levels of correctly folded protein. However, a disadvantage of the eukaryotic systems is 
that their optimal induction times are in the order of days whereas for prokaryotic systems 
it is in the order of hours. Additionally, P. pastoris cells need to be produced prior to use 
whereas competent E. coli cells required for transformation with plasmid DNA can be 
stored frozen. A decision to express Cal B in E. coli was undertaken due to the ease of 
downstream genetic modification in prokaryotic systems.
170
 Additionally prokaryotic 
systems are fast growing and have good protein production rates.  
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Figure 2.1: Plasmid map of the Cal B gene in a pPIC9 vector incorporating the ampicillin 
resistant gene for expression in P. pastoris. 
 
2.4.1 Amplification of the pPIC9 Cal B construct in One Shot
®
 Top10 competent 
cells 
 
The Cal B gene was cloned on the pPIC9 plasmid between the unique XhoI and NotI 
restriction sites. To sub-clone the Cal B gene into a vector for expression in prokaryotic 
systems, the pPIC9 Cal B construct (0.5 µL, 200 ng/µL) was amplified in One Shot
®
 
Top10 competent cells, according to the manufacturer‟s protocol. The transformation of 
One Shot
®
 Top10 competent cells with the pPIC9 Cal B plasmid was plated onto Luria-
Bertani (LB) agar plates containing 100 µg/mL ampicillin (LB amp) for selection. Single 
colonies were picked off the LB amp plates and inoculated overnight in LB amp media. 
The overnight cultures were incubated at 37 °C for 18 hours. Glycerol stocks (25%) were 
made with the cultures for long term storage at – 80 °C. The plasmid DNA was extracted 
and purified from the remaining bacterial cells and the concentration of the double 
stranded DNA was measured.  
 
Restriction digest analysis, using the restriction enzymes SphI and XbaI, was used to 
identify colonies with the gene incorporated. The restriction digest analysis, by agarose gel 
electrophoresis, and subsequent DNA sequencing of the Cal B gene showed that the Cal B 
samples still had the gene incorporated (Figure 2.2). All the plasmid DNA samples were 
sequenced to verify the restriction digest analysis results.  
pPIC9 Cal B 
8998 bp 
Alpha Factor 
Cal B 
AmpR 
HIS4 
3' AOX1 Fragment 
5' AOX1 promoter fragment 
pBR322 origin 
3' AOX1 TT 
Nco I (4608) 
Nde I (6832) Not I (2211) 
Sac II (2076) 
Sph I (5759) 
Stu I (4238) 
Xba I (3008) 
Xho I (1193) 
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Lane 1: DNA marker, Lanes 2 – 8: eight colony samples that were subjected to restriction digest analysis 
showing the gene was still incorporated in the plasmid and in the correct orientation. 
Figure 2.2: Agarose gel analysis of the restriction digest. 
 
2.4.2 Amplification of the Cal B gene 
 
The Cal B gene was amplified using primers designed for the vectors pET16b (Novagen) 
and Champion™ pET SUMO (Invitrogen) (Table 2.7). The pET16b vector was chosen as a 
general expression vector for E. coli and the Champion™ pET SUMO vector was chosen 
because the vector incorporates fusion of the SUMO protein, which aids solubility of the 
fusion protein produced. The Cal B was amplified by PCR, purified and sub-cloned into 
the appropriate vectors. 
 
Primer DNA sequence 5’ – 3’ 
pET16b forward sequence CGA GTC CAT ATG CGT CTA CCT 
TCC GG 
 
pET16b backward sequence TGA TCG CTC GAG TTA GGG GGT 
GAC G 
 
pET SUMO forward sequence ATG CGT CTA CCT TCC G 
 
 
pET SUMO backward sequence TTA GGG GGT GAC GAT GC 
 
 
 
Table 2.7: Primers for cloning Cal B into the vectors pET16b and Champion
™
 pET SUMO. 
 
 
 
1      2       3       4      5       6       7       8 
Kb 
6 
3 
10 
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2.4.3 Sub-cloning the Cal B gene into pET16b and Champion™ pET SUMO 
vectors 
 
2.4.3.1 Sub-cloning the Cal B gene into the pET16b plasmid 
 
There are several features of the pET16b Cal B construct that include the Cal B gene, the 
ampicillin resistant gene, lacI gene, restriction enzyme sites and the T7 lac promoter 
(Figure 2.3).  
 
 
 
Figure 2.3: Plasmid map of Cal B gene in an E. coli pET16b expression vector. 
 
The Cal B gene is the gene of interest and the ampicillin resistant gene allows selection of 
only the E. coli cells that harbour the pET16b Cal B construct by simply growing the 
bacteria on an agar plate containing ampicillin. At the N-terminus of the Cal B gene is also 
a short sequence of histidine residues (HIS tag) that allows for identification and 
purification of the protein. The restriction enzyme sites are sites which contain a specific 
sequence of bases that a restriction enzyme recognises and is able to cut. Restriction 
enzymes can be used to cut the plasmid to incorporate a gene of interest or can be used to 
cut a plasmid, a circular piece of DNA, into a linear strand for analysis. Most importantly 
of all, the pET16b Cal B construct is under the control of the T7 lac promoter system, 
which also includes the lacI gene.  
 
pET 16b Cal B 
6668 bp 
AmpR 
lacI 
Cal B 
T7lac 
Bgl 
Eco RI (6666) 
Mlu 
Nco 
Nde 
Sac II (464) 
Sph 
Xba 
Xho I (324) 
I (1288) 
I (1349) 
I (1388) 
II (1454) 
I (1651) 
I (2176) 
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The lacI gene encodes for the lac repressor which is continuously expressed in the host 
chromosome as well as in the plasmid. The lac repressor binds to the T7 lac operator on the 
plasmid and prevents the basal level production of T7 RNA polymerase, the enzyme that 
transcribes the Cal B gene. The lac repressor also binds to the host chromosome blocking 
the lacUV5 promoter, which is the promoter for the T7 RNA polymerase gene. Isopropyl-
β-D-1-thiogalactopyranoside (IPTG), a lactose analogue, is added to induce the expression 
of the Cal B gene. IPTG binds to the lac repressor which changes its conformation 
preventing it from binding to the T7 lac operator and the lacUV5 promoter. As a result, T7 
RNA polymerase is produced and is able to bind to the T7 lac promoter and transcribe the 
Cal B gene. 
 
To sub-clone the Cal B gene into the pET16b vector between the unique NdeI and XhoI 
restriction sites, a double digestion reaction of the vector and gene was prepared. The 
restriction enzymes used were NdeI and XhoI. The restriction digest reaction was incubated 
at 37 °C for 3 hours. After 3 hours, a DNA analytical agarose gel was run to check if the 
reaction was complete. After it was complete, the reaction mixtures were run on an agarose 
gel to separate the vector from the multiple cloning sites and the gene with the restriction 
sites. The DNA was then extracted from the gel under a blue light transilluminator and 
purified using a QIAquick Gel Extraction Kit. 
 
Ligation reactions with different ratios of insert to vector, 1:1 and 3:1, were prepared. The 
amount of insert to vector to use was calculated from Eq. 5 (Appendix 5). The ligation 
reactions were incubated at 4 °C overnight.  
 
A transformation of both the ligation reactions, 1:1 and 3:1 ratio of insert to vector, into 
One Shot
®
 BL21 competent cells following the manufacturer‟s protocol was prepared. 
Two volumes of the transformation reaction were plated, 50 µL and 100 µL, onto LB amp 
plates. Both transformation reactions were successful but the 3:1 ratio of insert to vector 
produced more colonies. 
 
To obtain plasmid DNA, LB amp media was inoculated with a single colony picked from 
the transformation reaction and incubated at 37 °C for 18 hours. From the overnight 
cultures, glycerol stocks were made (25%) and the plasmid DNA was harvested and 
purified using a QIAGEN Plasmid Prep Kit. 
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A restriction digest analysis of the pET16b Cal B plasmid DNA was prepared to ensure 
that the gene was incorporated in the correct orientation. The restriction enzymes used for 
the analysis were SacII and MluI. When the Cal B gene is incorporated in the correct 
orientation, the fragment sizes expected are 1.7 kb and 4.9 kb but if the gene is 
incorporated incorrectly then the fragment sizes expected are 1.0 kb and 5.6 kb. The 
samples were also sequenced to confirm the results of the restriction digest analysis. 
Standard T7 forward and reverse primers were used for sequencing. Both the results of the 
restriction digest analysis and sequencing showed the gene was incorporated in the correct 
orientation in the pET16b plasmid. 
 
2.4.3.2 Sub-cloning the Cal B gene into the Champion™ pET SUMO plasmid 
 
The Champion™ pET SUMO expression system was designed to possibly increase 
expression of recombinant proteins in E. coli and enhance the solubility of partially 
insoluble protein. The pET SUMO Cal B construct has similar features to the pET16b Cal 
B construct including the Cal B gene, the lacI gene, the T7 lac promoter, the HIS tag and 
restriction enzyme sites (Figure 2.4). In addition to the HIS tag, in pET SUMO Cal B there 
is a SUMO tag on the N-terminus which enhances the solubility of the protein of interest. 
In pET SUMO Cal B, a kanamycin resistant gene is used rather than ampicillin which 
again allows for selection of the E. coli cells that have the pET SUMO Cal B plasmid 
incorporated. The SUMO gene is fused to the N-terminus and can be cleaved using SUMO 
protease to produce our native protein, Cal B. 
 
To sub-clone the Cal B gene into the Champion™ pET SUMO Cal B vector, two ligation 
reactions were set up with a 1:1 and 3:1 ratio of insert to vector. The ligation reactions 
were incubated at 4 °C overnight. The Champion™ pET SUMO Cal B plasmid was 
transformed into Mach1 T1-R competent cells. The transformation reactions were plated 
onto kanamycin inoculated agar plates (LB kan). The plates were incubated at 37 °C 
overnight. The ligation reaction with a 1:1 ratio of insert to vector provided the best 
conditions and the colonies were subsequently used for overnight cultures.  
 
 72 
 
  
Figure 2.4: Plasmid map of Cal B gene in the E. coli Champion
®
 pET SUMO expression 
vector with a kanamycin resistant gene. 
 
From the overnight cultures, glycerol stocks (25%) were prepared and the plasmid DNA 
was harvested and purified. To ensure the Cal B gene had been incorporated in the correct 
orientation, a restriction digest analysis was prepared using the restriction enzymes SphI 
and BamHI. The fragment sizes expected if the Cal B gene had been incorporated with the 
correct orientation were 0.8 kb and 5.8 kb. If the orientation had been incorrect, the 
fragment sizes would have been 1.5 kb and 5.1 kb. The analysis showed that only samples 
1, 3, 5, 8, 11-13 and 19-20 had the Cal B gene incorporated with the correct orientation. 
These samples were also submitted for sequencing, using the standard T7 forward and 
reverse primers, which confirmed the results of the restriction digest analysis.  
 
After identification of a construct with a gene of the correct orientation, the Champion™ 
pET SUMO Cal B vector was then transformed into One Shot BL21(DE3) competent cells. 
Overnight cultures of 20 colonies were prepared and glycerol stocks (25%) were prepared 
from the overnight cultures. The plasmid DNA was harvested and purified from the 
remaining bacterial cells. 
 
 
pET-SUMO Cal B 
6603 bp 
Cal B 
SUMO 
His Tag 
Kanamycin Resis. Gene 
lacI 
T7 lac promoter 
pBR322 ori 
Bam 
Eco RI (572) 
RV (5625) 
Mlu I (6071) Nde I (296) 
Pst 
Sac II (1481) 
Sph I (1) 
Xba I (256) 
HI (815) 
I (1509) 
Eco 
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2.5 Expression of Cal B from pET16b and pET SUMO in E. coli competent cells 
 
Having amplified and sub-cloned the Cal B gene into two E. coli expression vectors, 
pET16b and pET SUMO, various expression and protein production conditions were 
examined for the synthesis of soluble and active Cal B. 
 
2.5.1 Initial expression studies of Cal B from pET16b and pET SUMO in 
BL21(DE3) competent cells at 37 °C with IPTG 
  
To determine whether the pET16b Cal B and pET SUMO Cal B constructs would yield 
over-produced protein, an initial expression study was conducted. Previously prepared 
glycerol stocks (25 %) of BL21(DE3) E. coli competent cells transformed with the pET16b, 
pET16b Cal B and pET SUMO Cal B constructs were streaked onto LB plates with the 
appropriate antibiotic for selection. The LB plates were incubated at 37 °C overnight. The 
growth of single colonies on all of the LB plates was successful. Overnight cultures were 
prepared by inoculating LB media with the appropriate antibiotic and then with a single 
colony from the corresponding LB plates. The cultures were incubated in a 37 °C shaking 
incubator overnight. All the overnight cultures grew successfully and were used to 
inoculate LB media (1 in 100 dilution factor) possessing the correct antibiotic for retention 
of the appropriate plasmid. The cultures were first grown at 37 °C to an optical density 
(OD600) of ~ 0.6, where the cell culture growth is in the exponential phase. The cell 
cultures were then induced with IPTG and the temperature was reduced to 30 °C, where 
the cells were left to grow for 18 hr. In order to determine which expression system 
produced the most soluble and active Cal B as a function of time, time point protein 
samples were taken at t0, t2, t3 and t18 hours post induction. The samples were centrifuged 
to obtain the bacterial cell pellet. Samples were taken at t0 to examine the basal level of 
expression prior to induction with IPTG. The samples were chemically lysed using 
BugBuster
®
 Protein Extraction Reagent, according to the manufacturer‟s instruction. The 
insoluble and soluble fractions of cell free extract were then analysed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE, Figure 2.5). 
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Figure 2.5: SDS-PAGE of the soluble (top) and insoluble fractions (bottom) of the samples 
taken during the initial expression studies. 
Top SDS gel: Solub1e fractions, Bottom SDS gel: Insoluble fractions, L = protein ladder, Lane 1 = pET16b 
Cal B t0, Lane 2 = pET16b Cal B t2, Lane 3 = pET16b Cal B t3, Lane 4 = pET16b Cal B t18, Lane 5 = 
pET16b t0, Lane 6 = pET16b t2, Lane 7 = pET16b t3, Lane 8 = pET16b t18, Lane 9 = pET SUMO Cal B t0, 
Lane 10 = pET SUMO Cal B t2, Lane 11 = pET SUMO Cal B t3 and Lane 12 = pET SUMO Cal B t18.  
 
The SDS-PAGE of the soluble fractions show that there was no over-produced band of 
protein that corresponds to Cal B (33 kDa)
140
 or the Cal B SUMO fusion protein (46 kDa). 
In the insoluble fractions, it is more evident that there are bands of over-produced protein 
in both the pET16b Cal B (lanes 2-4) and pET SUMO Cal B (lanes 10-11) systems. The 
over-produced band of protein in the pET SUMO Cal B expression was larger in size (46 
kDa) due to the SUMO fusion protein and 6xHis-tag, which in total is 13 kDa in size. The 
results of the SDS-PAGE also indicate that Cal B was produced about 2 hours after 
addition of IPTG in both the pET16b Cal B and pET SUMO Cal B systems (lanes 2 and 
10). The observed inclusion body formation may be due to several factors, as there are 
three stages in which expression problems can occur: the transcription of the Cal B gene, 
 1     2     3    4  L   5  6    7    8   L   9   10 11  12 kDa 
 
175 
 
80 
58 
46 
 
30 
 
25 
 
17 
 
 
33 kDa 
46 kDa 
1    2     3     4    L   5    6    7    8   L   9   10  11  12 
 
33 kDa 
46 kDa 
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the translation of the mRNA and post-translational events such as the folding of the peptide 
chains. As there is over-production of Cal B both from the pET16b and pET SUMO 
systems, although largely as inclusion bodies, it can be assumed that transcription and 
translation of the Cal B gene was successful.  The results indicate that incorrect folding of 
the protein, in particular the three disulfide bonds of Cal B, may be the problem. At this 
point, a decision to focus initially on the pET16b plasmid was made. 
 
2.5.2 Expression of Cal B from pET16b in BL21(DE3) competent cells at  
37 °C without IPTG and induction at 26 °C 
 
In order to obtain increased levels of soluble Cal B, another set of expression conditions 
was investigated. It has previously been reported that a basal level of T7 RNA polymerase 
exists when under the control of the lacUV5 promoter in DE3 lysogens such as 
BL21(DE3).
167
 Although our plasmid is also under the influence of the lac operator, the 
pET16b plasmid originating from the Turner lab had been successfully used previously for 
the production of protein without addition of an inducer such as IPTG.
171,172
 This 
uninduced method of protein production may be due to incomplete binding of the lac 
repressor to the operator. This results in a basal level of T7 RNA polymerase which can 
bind to the lac operator and allow transcription of the Cal B gene. Additionally, although 
an external inducing source was not used, a lowering of the temperature from 30 °C to  
26 °C at induction was proposed to aid folding of the protein. A reduction in induction 
temperature has been found to be important in the prevention of the formation of inclusion 
bodies or insoluble aggregates.
173
 The rate of protein folding was not directly affected by 
reduced expression temperatures, however, the rate of transcription and translation are 
directly affected by low expression temperatures. The increase in functional protein 
expression was a result of sufficient time for protein refolding.
174-176
 
 
A culture containing a single colony of pET16b Cal B or pET16b was grown at 37 °C. The 
cultures were then induced by incubating at 26 °C overnight. The bacterial cell pellets were 
harvested by centrifugation and then mechanically lysed to obtain the soluble and insoluble 
fractions. The soluble fractions were analysed by SDS-PAGE and Western blot (Figure 
2.6). A Western blot is an analytical technique used for identification of specific proteins in 
an extract. Initially, the proteins were separated by size using SDS-PAGE and then blotted 
onto polyvinylidene fluoride membrane where proteins can be identified using specific 
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antibodies to the target protein. The Cal B protein has a HIS-tag which can be used for 
identification with the monoclonal anti-polyhistidine antibody. Staining of the membrane 
to display histidine tagged protein is carried out by using a second anti-body coupled with 
a staining agent. 
 
  
 
Figure 2.6: Western blot (left) and SDS-PAGE gel (right) of small scale non-induced 
production of Cal B from pET16b. 
L = protein ladder, Lanes 1-2 = Cal B expressed from pET16b Cal B without addition of IPTG. 
 
From the Western blot and SDS-PAGE gel, it is evident that the Cal B gene is over-
produced in a soluble form compared to the previous study discussed in section 2.5.1. 
Additionally, the Western blot illustrates the production of truncated HIS-tagged proteins 
resulting from either incomplete translation or degradation products arising from protease 
activity on the Cal B protein. 
 
2.5.2.1 Determining activity of the recombinant Cal B 
 
The activity of the soluble recombinant Cal B was tested using the assay described in 
section 2.3. The biotransformation of 2-bromopropionic acid 35 into n-butyl-2-
bromopropionoate 114 was carried out using the soluble fraction of recombinant Cal B. 
The pET16b vector was also expressed under the same conditions. Samples were taken and 
analysed by chiral HPLC, however after 24 h no product was observed. After 48 h very 
little product was observed so the reactions were repeated and monitored for 4 days. Even 
after 4 days, very little product was observed and hence calculation of enantiomeric excess 
and enantioselectivity was not possible. Additionally, there was little difference in activity 
between the recombinant Cal B reaction and the control. 
 L  1    2       L    1     2 
  
33 kDa 
33 kDa 
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2.5.2.2 para-Nitrophenyl acetate high-throughput assay 
 
As the results to the HPLC assay were inconclusive, a faster and easier way to determine 
the activity of the recombinant Cal B was needed. The pNPA assay, as described in section 
1.8.2.2, can be used to determine the hydrolysis activity of the recombinant Cal B (Scheme 
1.23). The assay was conducted in buffer at pH 7.4 containing recombinant Cal B and 
initiated by addition of the pNPA substrate as a solution in DMSO (50 mM). A graph was 
plotted of absorption versus time (Figure 2.7). The gradient of the curve showed that the 
recombinant Cal B had little difference in activity when compared to the pET16b negative 
control. 
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Red = soluble fraction of recombinant Cal B, Blue = soluble fraction of pET16b 
Figure 2.7: pNPA assay graph of time vs. absorbance for pET16b Cal B. 
 
2.5.2.3 Purification of pET16b Cal B  
 
To characterise the specific activity of Cal B, the recombinant Cal B expressed from 
BL21(DE3) E. coli cells grown at 37 °C with induction at 26 °C was purified using affinity 
chromatography. The HIS-tagged protein was easily separated from the non HIS-tagged 
proteins by using a HiTrap Chelating HP affinity column. The column was supplied free of 
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metal ions and once it was charged with NiSO4
2-
 it was used to purify the protein. A single 
exposed histidine residue may result in adsorption of the protein onto Cu
2+
, while two 
vicinal histidine residues are needed for absorption on Zn
2+
 and NiSO4
2-
 ions and therefore 
NiSO4
2
 ions was used for the purification of the recombinant HIS-tagged Cal B. The HIS-
tagged Cal B can be separated from the truncated HIS-tagged proteins and other proteins 
that contain histidine residues by using a gradient solvent profile. Increasing the 
concentration of imidazole leads to separation of different proteins. 
 
A fresh cell free extract was prepared by resuspending the bacterial cell pellet in potassium 
phosphate buffer and then subjecting the suspension to mechanical lysing (sonication with 
protein inhibitor cocktail and lysozyme). The cell free extract of BL21(DE3) pET16b Cal 
B was purified initially on a linear gradient solvent profile (Figure 2.8). 
 
 
 
 
 
Figure 2.8: UV chromatogram profile of the linear gradient purification of Cal B. 
 
The UV chromatogram showed a large peak of over 4000 mAU, consisting of protein that 
does not bind to the column at all (A1), followed by a second peak, eluting at 0.5 M 
imidazole concentration (B1). Fractions collected from the purification were analysed by 
SDS-PAGE to see which fractions contain Cal B (Figure 2.9).  
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L = protein ladder 
Figure 2.9: SDS-PAGE of all the fractions from the linear gradient purification of Cal B. 
 
From the SDS-PAGE, it can be seen fraction A1 contains proteins of various sizes that 
have not bound to the column. A protein of 33 kDA, the correct size for Cal B, is present in 
fractions B3 - B11.  
 
To separate the tailing peak in fractions B5-B9, some of which contain Cal B, a step 
gradient method was developed which consisted of holding the gradient at 10%, 20%, 30% 
and 100% salt concentration for 10 mL. The purification was repeated using this method 
and analysis of some of the fractions by SDS-PAGE showed that there was very little Cal 
B in the fractions as a significant amount was lost through purification. The activity of the 
recombinant Cal B was not recorded at this time. 
 
Now that a basic purification method had been established, attention was turned to the 
expression of significantly more soluble and active Cal B. 
 
2.5.3 Optimisation of expression of Cal B in BL21(DE3) E. coli cells 
 
A number of parameters were investigated to optimise production of soluble and active 
protein, including temperature of induction and the final concentration of IPTG, both of 
which affect transcription, translation and post-translational events.
177,178
 A set of 
expression trials on a 250 mL scale using three different induction temperatures, 30 °C, 26 
°C and 16 °C and four different final IPTG concentrations, 1 mM, 0.5 mM, 0.025 mM and 
0 mM, was set up to establish the optimum appropriate conditions for maximum 
production of soluble and active Cal B protein. 
 
L A1                                         A12 L B1                                                B12 L C1                  C6  L 
Cal B 
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BL21(DE3) E. coli competent cells transformed with pET16b Cal B were used for the 
expression study. The expression was conducted in LB amp media for plasmid selection. 
Once the twelve cultures had grown to an OD600 of ~ 0.6, they were each induced under 
different conditions. Samples (2 mL) of the cultures were taken at t0-t6, t8 and t24 hrs post-
induction for analysis by SDS-PAGE (Figure 2.10 – 2.12). 
 
 
 
Figure 2.10: SDS-PAGE analysis of the time point protein samples from the induction at 
30 °C. 
 
 
 
Figure 2.11: SDS-PAGE analysis of the time point protein samples from the induction at 
26 °C. 
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Figure 2.12: SDS-PAGE analysis of the time point protein samples from the induction at 
16 °C. 
 
The SDS-PAGE gels in Figure 2.10-2.12 showed overexpression of Cal B at 30°C and 
26°C from about 1-2 h post-induction. The 16 °C expression studies revealed that Cal B 
was only produced 4-6 h post-induction. The SDS-PAGE gels also show that each 
expression system yielded different quantities of recombinant Cal B. 
 
From the SDS-PAGE gels in Figure 2.10-2.12, it is evident that Cal B is overproduced but 
it is not known whether this Cal B is soluble or active. To determine the solubility of the 
Cal B, the bacterial cell pellets were obtained by centrifugation and chemically lysed. The 
soluble and insoluble fractions were then analysed by SDS-PAGE. From the SDS-PAGE 
gels in Figure 2.10-2.12, twenty two promising time-point samples were selected for 
further study (Figure 2.13).  
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Figure 2.13: SDS-Page analysis of the soluble and insoluble fractions from chemical  
lysing of the bacterial cell pellets at some chosen time points. 
L = protein ladder, s = soluble fraction, i = insoluble fraction, Lane 1 = 16 °C 1 mM 24 hr, Lane 2 = 16 °C 
0.5 mM 24 hr, Lane 3 = 16 °C 0.025 mM 24 hr, Lane 4 = 16 °C 0 mM 24 hr, Lane 5 = 26 °C 1 mM 4 hr, 
Lane 6 = 26 °C 1 mM 24 hr, Lane 7 = 26 °C 0.5 mM 5 hr, Lane 8 = 26 °C 0.5 mM 24 hr, Lane 9 = 26 °C 
0.025 mM 4 hr, Lane 10 = 26 °C 0.025 mM 8 hr, Lane 11 = 26 °C 0.025 mM 24 hr, Lane 12 = 26 °C 0 mM 
5 hr, Lane 13 = 26 °C 0 mM 24 hr, Lane 14 = 30 °C 1 mM 3 hr, Lane 15 = 30 °C 1 mM 8 hr, Lane 16 = 30 
°C 0.5 mM 5 hr, Lane 17 = 30 °C 0.5 mM 24 hr, Lane 18 = 30 °C 0.025 mM 3 hr, Lane 19 = 30 °C 0.025 
mM 4 hr, Lane 20 = 30 °C 0.025 mM 24 hr, Lane 21 = 30 °C 0 mM 4 hr, Lane 22 = 30 °C 0 mM 24 hr. 
 
From the SDS-PAGE gels in Figure 2.13, it is apparent that many of the protein samples 
yielded insoluble Cal B such as can be seen in lanes 1-3. These lanes correspond to the 
expression studies conducted at 16 °C with 0.025-1 mM IPTG. However, in lane 4 this 
expression conditions (16 °C with 0 mM IPTG) provided Cal B that was partially soluble. 
The production of partially soluble Cal B can also be seen in lanes 6, 8, 11-13, 15-17 and 
           L   L   9s    9i  10s10i  11s 11i 12s 12i 13s13i 14s 14i 15s 15i 16s 16i            
  L     L   L    17s  17i   18s  18i  19s  19i   20s  20i  21s  21i  22s  22i      
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20-22. The expression conditions that furnished partially soluble Cal B are summarised in 
Table 2.8. 
 
Temperature 
(°C) 
Final IPTG conc. 
(mM) 
16 0 
26 1 
26 0.5 
26 0.025 
26 0 
30 1 
30 0.5 
30 0.025 
30 0 
 
Table 2.8: A summary of the expression conditions that yielded partially soluble Cal B. 
 
Measurement of the activity of the soluble fractions from the chemical lysis of the bacterial 
cell pellets using the pNPA assay showed that there were several expression conditions 
that yielded soluble and active Cal B. Two of the conditions, 30 °C 0 mM IPTG and 16 °C 
0 mM IPTG, yielded significantly more active enzyme (Figure 2.14). These two expression 
conditions were repeated on a larger scale. Samples were taken at t0 and t24 hrs after 
induction and analysed by SDS-PAGE (Figure 2.15) and centrifuged to obtain cell pellets. 
These cell pellets were chemically lysed and the soluble and insoluble fractions were also 
analysed by SDS-PAGE (Figure 2.16-2.17).  
 
The SDS-PAGE gels in Figure 2.15 show a basal level production of Cal B in lane 2. This 
is from the presence of basal levels of T7 RNA polymerase in BL21(DE3) competent cells. 
Interestingly, there was no basal level of production in lane 1. In lanes 3 and 4, it is evident 
that Cal B is overproduced in both the expression conditions. The SDS-gels of the soluble 
and insoluble fractions of protein (Figure 2.16-2.17), show that although the majority of 
the expressed Cal B is insoluble there is also a significant amount of soluble Cal B. Now 
that the solubility of the recombinant Cal B had been established, the activity of the soluble 
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Cal B was investigated. The pNPA assay was used to test the activity of the soluble 
fractions. The pNPA assay again showed that the soluble Cal B was active from both the 
expression conditions. However, the soluble Cal B from the 16 °C 0 mM IPTG was more 
active than the soluble fraction from the 30 °C 0 mM IPTG expression. The soluble and 
purified Cal B were also used to test the stability of Cal B when stored at  
– 4 °C and the data showed that Cal B did not lose activity after 1 week (discussed in detail 
in section 2.6). 
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Green = 16 °C 0 mM IPTG, Pink = 30 °C 0 mM IPTG, Blue = 26 °C 0 mM IPTG, Yellow = 26 °C 0.5 mM 
IPTG. 
Figure 2.14: pNPA assay of the soluble fractions of recombinant Cal B produced using 
various conditions conducted in potassium phosphate buffer at pH 7.4 and 25 °C. 
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Figure 2.15: SDS-PAGE gel of the samples taken at t0 and t24 hrs after induction. 
L = protein ladder, Lane 1 = 30 °C t0, Lane 2 = 16 °C t0, Lane 3 = 30 °C t24, Lane 4 = 16 °C t24. 
 
 
 
Figure 2.16: SDS-PAGE gel of the soluble fractions from the chemically lysed protein 
samples. 
L = protein ladder, Lane 1 = 30 °C t0, Lane 2 = 16 °C t0, Lane 3 = 30 °C t24, Lane 4 = 16 °C t24. 
 
 
Figure 2.17: SDS-PAGE gel of the insoluble fractions from the chemically lysed protein 
samples. 
L = protein ladder, Lane 1 = 30 °C t0, Lane 2 = 16 °C t0, Lane 3 = 30 °C t24, Lane 4 = 16 °C t24. 
     L        1            1          2             2       L         3         3             4            4 
     L        1           1         2            2          3          3          4            4           L 
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As the 16 °C 0 mM IPTG sample demonstrated the higher activity, the protein was purified 
on a HiTrap chelating column to investigate the specific activity of Cal B. The basic 
purification protocol described in 2.5.2.3 was used to purify the Cal B. The fractions from 
the purification were analysed by SDS-PAGE and they showed very little Cal B protein 
post-purification. Purification of HIS-tagged Cal B from the 30 °C 0 mM IPTG expression 
under the same column conditions and methods also resulted in no Cal B being visible by 
SDS-PAGE. 
 
At this point a decision was taken to change the strain of E. coli cells under which Cal B 
was expressed to establish whether increased levels of recombinant Cal B could be 
produced. 
 
2.5.4 Expression of pET16b Cal B from Origami 2(DE3) E. coli cells 
 
Cal B contains 3 disulfide bonds which need to be formed in the reductive atmosphere of 
the cytoplasm in the BL21(DE3) E. coli. competent cells. Research into the development 
of new competent E. coli. cells that aid the correct folding of disulfide bonds was carried 
out. One paper, published in 2006, has been reported to express Cal B in Origami 2(DE3) 
E. coli. competent cells.
169
 This strain of E. coli is characterised by its thioredoxin 
reductase and glutathione reductase deficiency. These cells have a more oxidative 
cytoplasm to aid the formation of disulfide bonds. The expression in these cells is under 
the lac promoter as in the BL21(DE3) E. coli. competent cells. The pET16b Cal B 
construct and Origami 2(DE3) cells were therefore compatible. Origami 2(DE3) cells were 
slow growing and require 24 hrs growth. The transformation efficiency was also very low, 
yielding only 3-100 colonies unlike the BL21(DE3) cells which require only 16-18 hrs to 
form hundreds of colonies. Due to the low number of colonies, a single clone was picked 
and grown in an overnight culture before preparation of the DNA for sequencing. 
Sequencing results confirmed that the transformation of Origami 2(DE3) cells with the 
pET16b Cal B plasmid was successful.  
 
The conditions used in the expression trials described in section 2.5.3 were used for the 
expression of pET16b Cal B from Origami 2(DE3) cells. Samples were initially taken at t1-
t6, t8 and t24 hrs post-induction for analysis by SDS-PAGE. The cell pellets, obtained by 
centrifugation, were also chemically lysed to determine which conditions yielded the most 
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soluble Cal B. The soluble and insoluble fractions were analysed by SDS-PAGE and 
Western blot. One particular set of conditions, 16 °C 1 mM IPTG, yielded a strong band of 
soluble Cal B at t8 (Figure 2.18). 
 
 
 
 
         
 
 
Figure 2.18: SDS-gel and Western blot of the samples from 16 °C 1 mM IPTG expression 
of Cal B. 
 
The expression condition, 16 °C with 1 mM of IPTG, was repeated on a large scale and 
sampled hourly over 24 hrs to discover when the maximum soluble Cal B was produced. 
Analysis by SDS-PAGE and Western blot showed that maximum production of soluble 
Cal B was reached 16 hr post-induction. 
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Now that an expression system had been established, purification of the recombinant Cal B 
was carried out using a HiTrap chelating column. The basic purification system established 
in section 2.5.2.3 was used for the purification. The fractions from the purification were 
analysed by SDS-PAGE and Western blot which showed elution of Cal B at 0.4 M 
imidazole concentration (Figure 2.19). 
 
 
 
Figure 2.19: Western blot of the purification fractions show Cal B eluted in fractions B9-
C2. 
 
Initial experiments to determine the activity of the purified recombinant Cal B from 
Origami 2(DE3) E. coli were carried out using the pNPA assay. To remove the eluting 
buffer used in the purification, the fractions containing Cal B were concentrated by 
applying them to a Vivaspin concentrating column with a molecular weight cut off of 
30,000. The concentrated recombinant Cal B was then desalted using a PD10 column. The 
desalted and purified recombinant Cal B was used in the pNPA assay to test for hydrolysis 
activity (Figure 2.20). The pNPA activity test showed that the recombinant Cal B, 
produced in Origami 2(DE3) E. coli cells, was active. 
 
 
                                                             Cal B 
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Blue = Origami 2 Cal B, Pink = Origami 2 pET16b 
Figure 2.20: pNPA assay of the recombinant Cal B produced from Origami 2(DE3) E. coli 
cells. 
 
2.6 Characterisation of wild-type Cal B 
 
An assessment of the various expression experiments using both the BL21(DE3) and 
Origami 2(DE3) E. coli competent cells in the production of soluble and active Cal B 
resulted in a decision to repeat three of the optimised expression conditions to provide 
direct comparisons (Table 2.9). Kinetic characterisation of purified Cal B obtained from the 
three experiments was carried out using the para-nitrophenyl butyrate (pNPB) assay in 
triplicate and an average of the results are presented in Table 2.10. The kinetic experiments 
were carried out at 25 °C. Initial rates of activity were recorded for each purified sample of 
Cal B across a range of substrate concentrations (0-0.1 M). The Michaelis-Menton equation 
was used to calculate the kinetic parameters for each sample. Comparison of the data 
obtained with a published purification of Cal B from E. coli is shown in Table 2.10. 
 
The purified samples of Cal B produced in our laboratories gave comparable data to the 
published literature although there was some difference in the kcat and kM values. 
Interestingly the Cal B produced from Origami 2 cells appeared more active than that 
prepared from BL21 cells. The difference in kinetic parameters may be due to the correct 
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folding of the protein. As previously mentioned, Origami 2 cells promote disulfide bond 
formation to yield functional protein. The lower activity observed with BL21 cells maybe 
due to partially folded protein. It has also been reported that non-native partially folded 
protein can also have biological function, although the mechanism behind this is not 
understood.
180
  
 
Method Cells 
Induction 
temperature 
Final 
concentration 
of IPTG 
1 
 
Origami 2(DE3) 
 
16 °C 
 
1 mM 
 
2 
 
BL21(DE3) 
 
30 °C 
 
0 mM 
 
3 
 
BL21(DE3) 
 
16 °C 
 
0 mM 
 
 
Table 2.9: Three optimised expression conditions for the preparation of recombinant Cal B. 
 
In addition to characterising the different samples of Cal B, the stability of the purified  
Cal B was monitored over ten days. The pNPA assay was used to record the activity 1, 2, 7 
and 10 days post-purification (Figure 2.21 and Figure 2.22).  
 
Figure 2.21 shows that the activity of the Origami 2(DE3) sample declined quickly over 
ten days with only 20% of the original activity observed after ten days. The BL21(DE3) 
sample (Figure 2.22) maintained 100% activity over the first seven days and only showing 
a 23% reduction in activity when monitored ten days after it was first purified. Although 
Cal B produced from BL21(DE3) cells was of higher stability, higher activity was more 
important, so for future productions of Cal B, wild-type or variants, the Origami 2(DE3) 
expression conditions were used. 
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E. coli cells 
used for 
expression 
Induction 
temperature 
(°C) 
υmax  
(μM 
min
−1
) 
kM  
(μM) 
kcat 
(min
−1
) 
kcat/ kM  
(min
−1
 
μM−1) 
Specific activity 
(80 mM substrate  
μmol mg-1 min-1) 
Origami 
2(DE3) 
 
16 
 
438 
± 18 
 
27682 
± 2901 
 
4716 
± 27 
 
0.170 
± 0.018 
 
96.2 
 
BL21(DE3) 
 
30 
 
189 
± 13 
 
24930 
± 2833 
 
1921 
± 38 
 
0.077 
± 0.0095 
 
32.4 
 
BL21(DE3) 
 
16 
 
355 
± 41 
 
23291 
± 3296 
 
2466 
± 53 
 
0.106 
± 0.015 
 
53.1 
 
K12
179
 25 237 5492 2378 0.433 10.57 (20 mM) 
 
Table 2.10: Steady state kinetics of the different samples of Cal B calculated from the 
pNPB assay. 
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Pink = 0 days post-purification, Yellow = 1 day post-purification, Green = 2 days post-purification, Red = 7 
days post-purification, Blue = 10 days post-purification 
Figure 2.21: The stability of Origami 2 Cal B monitored over ten days using the pNPA 
assay. 
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Pink = 0 days post-purification, Yellow = 1 day post-purification, Green = 2 days post-purification, Red = 7 
days post-purification, Blue = 10 days post-purification 
Figure 2.22: The stability of BL21 16 °C Cal B monitored over ten days using the pNPA 
assay. 
 
2.7 Synthesis of fluorinated substrates  
 
Most of the synthetic approaches to 2-fluoropropionic acid 83 discussed in section 1.4.3 
involve the use of hazardous and toxic reagents such as elemental fluorine, hydrogen 
fluoride and DAST and as such were not deemed suitable for use in industrial research and 
downstream scale up reactions. In addition, many of these reagents would require 
expensive and specialist equipment to be put in place with elaborate safety regimes. 
Reagents that were identified as being suitable for subsequent downstream scale up 
reaction limited the studies to the synthesis of the fluorinated substrates, 2-fluoropropionic 
acid 83 and ester derivatives. Their chemical synthesis was required for use as substrates in 
subsequent biotransformation reactions and due to the lack of commercial availability of 
the monofluorinated esters and the high cost of 2-fluoropropionic acid 83 (£85/g).  
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2.7.1 Synthesis of n-butyl-2-bromopropionate 114 
 
n-Butyl-2-bromopropionate 114 was successfully prepared from 2-bromopropionic acid 35 
and n-butanol 117. The reaction was monitored by gas chromatography which showed the 
reaction was complete after 5 hours providing n-butyl-2-bromopropionate 114 in a yield of 
81%. This method was intended to be applied to the synthesis of n-butyl-2-
fluoropropionate 115 but due to the high cost of 2-fluoropropionic acid 83, this approach 
was not viable (Scheme 2.4). A more cost effective preparation of 2-fluoropropionic acid 
83 or an alternative method for the synthesis of n-butyl-2-fluoropropionate 115, not using 
2-fluoropropionic acid 83 as the starting material was needed. 
 
OH
O
F
O
n
-Bu
O
F
83 115
OH
117
 
 
Scheme 2.4:  Proposed synthesis of n-butyl-2-fluoropropionate 115 from 2-fluoropropionic 
acid 83 and n-butanol 117. 
Reagents and conditions: Toluene, conc. H2SO4, 130 °C, 5 h. 
 
The synthesis of the esters of 2-fluoropropionic acid using commercially available 
potassium fluoride (KF) as the fluorinating reagent has been reported.
181,182
 To generate the 
active fluorinating species, a mixture of hexadecyltributylphosphonium bromide (HTPB) 
and potassium fluoride was heated to 60 °C to form a semi-molten mass. HTPB acts as a 
phase transfer catalyst for the potassium fluoride making the fluoride ion more available. 
The substrate to be fluorinated was then added to give products with yields varying from 
60-89 %, depending upon the substrate to be fluorinated. This procedure was applied to the 
synthesis of n-butyl-2-fluoropropionate 115 from n-butyl-2-bromopropionate 114 with 
direct distillation of the product from the reaction mixture (Scheme 2.5). The distillate was 
analysed by 
19
F NMR, which revealed that the fluorination had not been successful and 
instead the distillate contained unreacted n-butyl-2-bromopropionate 114.  
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Scheme 2.5: Synthesis of n-butyl-2-fluoropropionate 115 using potassium fluoride 
as a fluorinating reagent. 
Reagents and conditions: a) potassium fluoride, HTPB, 60 °C. 
 
2.8 Development of an enantioselective screen for assaying Cal B mutants  
 
2.8.1 Development of a high throughput enantioselective screen for assaying Cal B 
mutants 
 
In order to screen the Cal B mutants, it was decided to adapt the existing pNPA screen. In 
place of the pNPA substrate, 4-nitrophenyl 2-bromopropionate 118 and 4-nitrophenyl 2-
fluoropropionate 119 was used (Figure 2.23). Hydrolysis of 4-nitrophenyl 2-
bromopropionate 118 and 4-nitrophenyl 2-fluoropropionate 119 by an active Cal B mutant 
resulted in production of 4-nitrophenol 98. The product 4-nitrophenol 98 was deprotonated 
under the alkaline assay conditions and is yellow in colour. The reaction was monitored by 
the increase in absorbance at 410 nm. 
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Figure 2.23: High throughput enantioselective screen substrates 4-nitrophenyl 2-
bromopropionate 118 and 4-nitrophenyl 2-fluoropropionate 119. 
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The synthesis of enantiopure 4-nitrophenyl 2-halopropionate 118 and 119 from the sodium 
salt of 4-nitrophenol 120 and (R)- or (S)-2-halopropionyl chloride 121 or 122 was proposed 
(Scheme 2.6).
183
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Scheme 2.6: Synthesis of single enantiomers of (R)- and (S)-4-nitrophenyl 2-
halopropionate 118 and 119.
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Reagents and conditions: 0 °C, NaOH (1 N), H2O. 
 
In theory when enantiopure 2-halopropionyl chloride 121 or 122 is used, enantiopure 4-
nitrophenyl 2-halopropionate 118 and 119 can be synthesised (Scheme 2.6). Each 
enantiomer can be assayed in separate wells in a high throughput enantioselective screen, 
from which an apparent enantioselectivity can be deduced. For true enantioselectivity 
values, conventional analysis methods would need to be used. Additionally, a chromogenic 
surrogate substrate is used and substrate competition is also not taken into consideration 
but if enantiopure 4-nitrophenyl 2-halopropionate 118 and 119 were available, this screen 
would reduce the need to grow each mutant up on a large scale and analyse by 
biotransformation reactions.  
 
A solution of sodium 4-nitrophenoxide 120 in sodium hydroxide (1N) and water was 
cooled in an ice bath before addition of racemic 2-bromopropionyl chloride 121. The 
mixture was allowed to stir in an ice bath for 5 minutes before precipitation of a white 
solid occurred. The crude 4-nitrophenyl 2-bromopropionate 118 was recrystallised from 
iso-hexane. The reaction was successfully completed using racemic 2-bromopropionyl 
chloride rac-121, resulting in racemic 4-nitrophenyl 2-bromopropionate rac-118. When 
enantiopure 2-bromopropionyl chloride 121 was used, racemisation of the chiral centre 
(confirmed using chiral HPLC) under the reaction conditions occurred resulting in the 
synthesis of racemic 4-nitrophenyl 2-bromopropionate rac-118. Application of this method 
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for the synthesis of enantiopure 4-nitrophenyl 2-halopropionate 118 and 119 was therefore 
abandoned. 
 
Other syntheses to produce enantiopure 4-nitrophenyl 2-halopropionate 118 and 119 were 
not proposed due to time constraints. 
 
2.8.2 HPLC assay of Cal B mutants 
 
In the absence of a high-throughput enantioselective assay, traditional methods for 
measuring the enantioselectivity of mutants generated in our studies were proposed. An 
HPLC assay that monitors the hydrolysis of ethyl-2-bromopropionate 123 and ethyl-2-
fluoropropionate 124 was proposed. The hydrolysis of ethyl-2-bromopropionate 123 and 
ethyl-2-fluoropropionate 124 was chosen over the esterification of 2-bromopropionic acid 
35 and 2-fluoropropionic acid 83 due to the environmentally friendly and cost 
effectiveness of using buffer over organic solvents (Scheme 2.7).  
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Scheme 2.7: Kinetic resolution of ethyl-2-bromopropionic acid 123 and ethyl-2-
fluoropropionate 124 using recombinant Cal B and its mutants. 
Reaction conditions: ethyl-2-halopropionic acid (5g/L), enzyme (2000 mg/reaction), potassium phosphate 
buffer (100 mM, pH 7.0, 4mL), ethanol (0.36 v/v%), incubated in a 30 °C shaker. 
 
2.8.2.1 Chiral HPLC method development 
 
In order to calculate the enantioselectivity of Cal B and its variants, HPLC methods to 
determine enantiomeric excess and conversion were required.  
 
Prior to normal phase chiral HPLC method development, as the assay was conducted in 
buffer, a suitable extraction method to obtain the products for analysis was required. To 
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this end, several organic solvents were tested for their ability to extract 2-bromopropionic 
acid 35 and 2-fluoropropionic acid 83 from buffer. Organic solvents such as ethyl acetate, 
dichloromethane and tert-butyl methyl ether (TBME) were used for this investigation. 
After extraction, the organic solvents were removed by evaporation before resuspending in 
iso-hexane and analysing the solution using the chiral HPLC method outlined in Table 2.11. 
TBME was found to extract 2-bromopropionic acid 35 from buffer the most efficiently. A 
sample of ethyl-2-fluoropropionate 124 left in buffer overnight was found to degrade to 
unknown products. It was at this point that a decision to screen the Cal B mutants with 
ethyl-2-bromopropionate 123 only was decided. The retention times of 2-bromopropionic 
acid 35 and ethyl-2-bromopropionate 123 were recorded (Table 2.12) 
 
HPLC 
Column 
Temp. 
(°C) 
Flow rate 
(ml/ min) 
Mobile Phase 
Hexane % 
Ethanol 
% 
TFA % 
Normal phase 40 1.3 98 1.9 0.1 
Column – Daicel Chiralpak
®
 AD-H - 5 μm particle size, 4.6 mm internal diameter, 250 mm column length 
Table 2.11: Normal phase HPLC method for the analysis of the enantiomeric excess of 2-
bromopropionic acid 35. 
 
Substrate 
Retention time 
(min) 
Assignment 
2-bromopropionic 
acid 35 
 
9.5 
(S)-2-bromopropionic 
acid
1 
10.3 
 
(R)-2-bromopropionic 
acid
1 
 
ethyl-2-
bromopropionate 123 
 
3.4 first eluting enantiomer 
3.5 
 
second eluting 
enantiomer 
 
1
 baseline separated. 
Table 2.12: Retention times of 2-bromopropionic acid 35 and ethyl-2-bromopropionate 
123 using the method outlined in Table 2.11. 
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In order to calculate the enantioselectivity of the Cal B mutants, a method on reverse phase 
HPLC was developed to measure the degree of conversion. A sample of 2-bromopropionic 
acid 35 and ethyl-2-bromopropionate 123 in buffer (100 μL) was added to acetonitrile (300 
μL) and subjected to analysis according to the method developed (Table 2.13). 
 
HPLC 
Column 
Temp. (°C) 
Flow rate 
(ml/ min) 
Mobile Phase 
Acetonitrile 
+ TFA 
(0.1%) % 
Methanol + TFA 
(0.1%) % 
Reverse phase 25 1 40 60 
Column – C18  
Table 2.13: Reverse phase HPLC method to analyse the conversion of the 
biotransformation reactions. 
 
When this protocol was tested with wild-type Cal B, it was found that 2-bromopropionic 
acid 35 did not extract sufficiently from the buffer so a decision to develop a new HPLC 
method to analyse enantiomeric excess and conversion in a single analysis run on a reverse 
phase chiral column was made. 
 
The reverse phase chiral column, Astec Chirobiotic
TM
 T, was deemed suitable for the 
resolution of 2-bromopropionic acid 35. Following extensive method development, chiral 
HPLC conditions to provide baseline separation of 2-bromopropionic acid 35 were 
determined (Table 2.14). The retention times of ethyl-2-bromopropionate 123 and 2-
bromopropionic acid 35 were recorded according to the method developed (Table 2.15).  
 
HPLC 
Column 
Temp. 
(°C) 
Flow rate 
(ml/ min) 
Mobile Phase 
Ammonium 
acetate buffer 
20mM pH 4.5 % 
Methanol % 
Reverse phase 
chiral 
5 0.5 10 90 
Column - Astec Chirobiotic
TM
 T - 5 μm particle size, 4.6 mm internal diameter, 250 mm column length 
Table 2.14: Reverse phase chiral method developed on an Astec Chirobiotic
TM
 T column for 
the baseline resolution of 2-bromopropionic acid 35. 
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Racemate 
Retention time 
(min) 
Assignment 
2-bromopropionic 
acid 35 
 
5.4 
(S)-2-bromopropionic 
acid
1 
6.0 
 
(R)-2-bromopropionic 
acid
1
 
 
ethyl-2-
bromopropionate 123 
6.9 
ethyl-2-
bromopropionate 
1
 baseline separated. 
Table 2.15: Retention times of 2-bromopropionic acid 35 and ethyl-2-bromopropionate 
123 on the reverse phase chiral method described in Table 2.14. 
 
For the analysis of biotransformations the reverse-phase chiral column, Astec Chirobiotic
 
TM
 T, was used under the method conditions outlined in Table 2.14. 
 
2.8.2.2 Mechanical lysis of bacterial cell pellets 
 
Due to the sensitive nature of the Astec Chirobiotic
TM
 T column, chemical lysis of 
bacterial cell pellet was no longer viable due to the surfactants in the chemical lysis agents. 
Alternative methods for lysis of bacterial cell pellets were considered. Mechanical lysis 
was determined to be the best alternative and a method was developed. A method was 
generated which initially had the bacterial cell pellets stored at -20 °C to aid the breakdown 
of the bacterial cell walls. The thawed cell pellets were then resuspended in buffer and 
lysozyme and protein inhibitor cocktail (PIC) were added to the suspension. The 
suspension was incubated at 37 °C for 20 minutes before sonication to generate the cell-
free extract. 
 
2.8.2.3 Protein extraction from buffer 
 
Removal of protein from samples before applying to an HPLC system prolongs the life and 
resolution of chiral HPLC columns. The protein was removed from the buffer by 
denaturisation at 95 °C for 5 minutes followed by centrifugation. This method allowed the 
majority of protein to be removed from a sample before analysis. The stability of 2-
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bromopropionic acid 35 and ethyl-2-bromopropionate 123 at 95 °C was also investigated. 
Ethyl-2-bromopropionate 123 was stable and did not hydrolyse within 25 minutes at 95 °C. 
Enantiopure 2-bromopropionic acid 35 also did not racemise at 95 °C over a period of 25 
minutes. 
 
2.9 Molecular modelling studies 
 
The main objective of this project was to identify a hydrolase with high enantioselectivity 
that was able to kinetically resolve the substrates 2-bromopropionic acid 35 and 2-
fluoropropionic acid 83. The screen of commercially available lipases afforded Cal B as a 
suitable candidate for both substrates, although with low enantioselectivity. Engineering of 
a protein has long been used as powerful tool to create novel enzymes capable of meeting 
the needs of industry. In order to obtain an enzyme with the required properties, directed 
evolution strategies are used. Different variant libraries of Cal B were generated using 
rational design and molecular biology methods. Each library was then screened using the 
reverse phase chiral HPLC assay described in section 2.8.2. The generation and screening 
of each library will be discussed in the following section. 
  
2.9.1 Rational design studies 
 
The published X-ray structure of Cal B was used for our molecular modelling studies 
(Figure 2.24, structure reference in Protein Data Bank 1TCA).
140
 When the DNA and 
protein sequence of our Cal B was aligned with the  protein and DNA sequence of 1TCA, 
2 mutations were observed at Ala57Thr and Thr89Ala. These mutations have been noted 
before and were attributed to natural variations of the lipase gene as a consequence of 
evolution.
169 
 
The Cal B active site consists of two pockets, one accommodating the acyl moiety and the 
other the alcohol moiety of the substrate. To enhance enantioselectivity for the kinetic 
resolution of secondary alcohols, engineering of the alcohol pocket has been reported. 
Mutagenesis of the alcohol pocket has resulted in many mutants with enhanced 
enantioselectivity.
159,184
 With the multitude of examples published concerning kinetic 
resolution of secondary alcohols, empirical rules were formed that summarised earlier 
results. The substituents of a substrate can be labelled small or large, relative to each other. 
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With the large substituent residing in the larger pocket and the smaller substituent residing 
in the smaller pocket of a lipase, prediction of the faster reacting enantiomer in a lipase 
catalysed kinetic resolution of secondary alcohols has been reported.
185
 This empirical rule 
was successfully applied to Cal B, when X-ray structures also showed two pockets of 
medium and large size.
186,187
 The stereogenic centre of our substrates, 2-bromopropionic 
acid 35 and 2-fluoropropionic acid 83, reside on the acyl moiety and engineering of the 
acyl pocket of Cal B has seldom been reported. 
 
  
 
Figure 2.24: left – flat ribbon structure of Cal B: right – Surface view of Cal B. 
 
2.9.2 Enzyme-Substrate docking models and proposed sites for mutagenesis 
 
A computational study was carried out aimed at elucidating the enzyme-substrate 
interactions that are responsible for the activity and ER observed. Accelrys Discovery 
Studio 1.6 and 2.0 were used to dock the substrates, 2-bromopropionic acid 35 and 2-
fluoropropionic acid 83, into the active site of Cal B using the known mechanism and the 
hydrogen bonding network to establish orientation. The energy of the protein was 
minimised and this structure was used for insight into residues that influence activity and 
enantioselectivity. 
 
The enantioselectivity of Cal B for the esterification  of 2-bromopropionic acid 35 with n-
butanol 117 is only moderately in favour of the (S)-enantiomer, ER = 2.5. This can be 
explained by modelling the (S)-enantiomer of 2-bromopropionic acid (S)-35 into the active 
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site of Cal B (Figure 2.25). The bromine of (S)-2-bromopropionic acid (S)-35 sits in the 
larger pocket of the active site (Figure 2.26). In comparison, when (R)-2-bromopropionic 
acid (R)-35 is docked into the active site of Cal B, the bromine atom sterically clashes with 
the narrow channel leading to the active site (Figure 2.27). 
 
 
 
Figure 2.25: The substrate (S)-2-bromopropionic acid (S)-35 modelled into the active site 
of Cal B with the large acyl pocket accomodating the bromine. 
 
         
 
Figure 2.26: CPK view of (S)-2-bromopropionic acid (S)-35 sits comfortably in the large 
acyl pocket of active site of Cal B. 
Bromine 
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Figure 2.27: The model of (R)-2-bromopropionic acid (R)-35 docked into the active site of 
Cal B with the bromine orientated towards the active site tunnel showed steric clashing 
with the wall of the narrow channel. 
 
As the mechanism of Cal B is known
140
, 2-bromopropionic acid 35 must be orientated with 
the carbon of the carbonyl group in close proximity to the nucleophilic serine (Ser105) of 
the catalytic triad. As 2-bromopropionic acid 35 contains a sterically demanding bromine 
atom, several models were generated with the bromine in the large pocket of the active site 
of Cal B. The results were used to inform subsequent focused mutagenesis at several 
positions namely Thr40, Ile189 and Ile285. These positions were chosen as they line the 
larger acyl pocket which accommodates the bromine atom. We hypothesised that by 
increasing the size of the acyl pocket this would facilitate the movement of the substrate in 
and out of the active site and thereby increase activity. It was proposed that replacement of 
larger amino acids such as Ile at position 189 with smaller amino acids like glycine and 
leucine would further reduce steric clashing between the bromine atom and the wall of the 
active site (Appendix 6). It is difficult to predict with any degree of certainty which 
residues will influence enantioselectivity. It was proposed that saturation mutagenesis at 
the positions identified would allow us some insight into this matter. By conducting 
saturation mutagenesis, investigation into interactions that govern enantioselectivity was 
probed by the different nature of the 20 natural amino acids. 
 
Bromine 
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The biotransformations of commercially available Cal B with 2-fluoropropionic acid 83 
revealed that the enzyme was selective towards the first eluting enantiomer. As fluorine is 
small in comparison to bromine, a rationale based upon steric demand is not sufficient to 
explain the enantioselectivity observed in our studies (Figure 2.28 and 2.29). Fluorine 
however is the most electronegative element and electronic factors could explain the 
enantioselectivity of Cal B towards 2-fluoropropionic acid 83. Some of the amino acid 
residues near the fluorine of (S)-2-fluoropropionic acid (S)-83 include Ser105, 3.34 Å away, 
Asp134, 3.99 Å away and Gln157, 3.66 Å away. Interactions that are possible with the 
fluorine of (S)-2-fluoropropionic acid (S)-83 include F-O electrostatic interactions. By 
conducting saturation mutagenesis at positions 134 and 157, a fluorine-enzyme interaction 
that stabilises the intermediate could be investigated. 
 
                           
 
Figure 2.28: (S)-2-Fluoropropionic acid (S)-83 modelled into the active site of Cal B with 
the fluorine atom positioned in the acyl pocket. 
 
Fluorine 
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Figure 2.29: (R)-2-Fluoropropionic acid (R)-83 modelled into the active site of Cal B with the 
fluorine atom positioned towards the entrance of the active site. 
 
In addition to the molecular modelling studies described above, reports by other research 
groups highlighted other potential sites for mutagenesis.
 188,189
 These residues were Thr138, 
Val190 and Leu278. It was also encouraging to see other research groups also targeting the 
same residues namely Asp134, Gln157 and Ile 189. Some of these groups were also 
undertaking mutagenesis of Cal B to increase ER, although our substrates differed, whilst 
others wanted to increase the hydrolysis activity of bulky substrates. The single mutant 
Leu278Ala was reported to have increased hydrolysis activity for bulky substrates and was 
included in our studies for this reason.
190 
The positions and mutations targeted in Cal B 
have been summarised in Table 2.16. 
 
 
 
 
 
 
 
 
 
 
Fluorine 
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Targeted sites in Cal B Mutations 
Thr40 
 
saturation library 
 
Asp134 
 
Ala, Ser, Thr, Asn 
 
Thr138 
 
saturation library 
 
Gln157 
 
Ala, Val, Leu, Ile, Ser, Thr, Asn 
 
Ile189 
 
saturation library 
 
Val190 
 
saturation library 
 
Leu278 
 
Ala 
 
Ile285 saturation library 
 
Table 2.16: A summary of the positions within Cal B targeted for mutation. 
 
2.10 Protein engineering and assaying of each Cal B mutant 
 
2.10.1 Protein engineering 
 
The Cal B variants discussed in section 2.9 were constructed using the wild-type Cal B 
gene as a template and the QuikChange
®
 Site-directed Mutagenesis Kit from Stratagene 
(Figure 2.30). Two strategies were used to generate the mutations outlined in Table 2.16. 
Codon optimised oligomers were used for the introduction of mutations at position 40, 134, 
157, 189, 278 and 285 and the NNK (N: adenine, cytosine, guanine and thymine; K: 
guanine and thymine) degenerate codon was used to generate saturation libraries at 
positions 138 and 190. The NNK degenerate codon involves 32 codons and all 20 amino 
acids as building blocks. 
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Figure 2.30: Transition state of the kinetic resolution of 2-bromopropionic acid 35 with 
positions of Cal B targeted for increased activity and enantioselectivity. 
 
After PCR, a DpnI digestion of the template DNA was carried out at 37 °C for 1 h. E. coli 
XL1-Blue cells were transformed with the mutated DNA, according to the manufacturer‟s 
protocol. The transformed cells were cultivated on LB amp agar plates and grown 
overnight in a 37 °C static incubator. Oversampling of the colonies from each 
transformation were prepared for overnight cultures. For the mutants generated using the 
NNK degenerate codon, 94 transformants are needed for 95% coverage of the 32 codons in 
a single position.
191
 The plasmid DNA of each culture was isolated and sequenced to verify 
that each mutation had been incorporated. In total 89 mutants were successfully 
synthesised and they are summarised in Table 2.17. Once sequencing had confirmed each 
mutation, the mutant DNA was used for the transformation of Origami 2(DE3) E. coli 
competent cells. Each mutant was grown up on a large scale (600 mL), according to the 
final protocol set out in section 2.5.4. The gene expression levels of each mutant were not 
recorded and the protein production levels were assumed to be comparable. The bacterial 
cell pellet of each mutant was stored at – 20 °C until needed for the HPLC assay. 
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Targeted sites in Cal B Mutants of Cal B successfully synthesised 
Thr40 
 
Ala, Cys, Asp, Glu, Gly, Ile, Lys, Met, Asn, Pro, Gln, Arg, 
Ser. 
 
Asp134 
 
Ala, Ser, Thr, Asn 
 
Thr138 
 
Ala, Cys, Asp, Glu, Gly, His, Lys, Leu, Met, Asn, Gln, Arg, 
Ser, Thr, Val, Tyr. 
 
Gln157 
 
Ala, Val, Leu, Ile, Ser, Thr, Asn. 
 
Ile189 
 
Ala, Cys, Phe, Gly, His, Leu, Asn, Pro, Gln, Ser, Thr, Val. 
 
Val190 
 
Ala, Cys, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, 
Gln, Arg, Ser, Thr, Trp, Tyr. 
 
Leu278 
 
Ala 
 
Ile285 
 
Ala, Cys, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, 
Gln, Arg, Ser, Thr, Val, Trp, Tyr. 
 
Table 2.17: A summary of all the mutants synthesised using protein engineering. 
 
2.10.2 Screening of the Cal B mutants using the HPLC assay 
 
The reverse phase chiral HPLC assay was used to determine the effects of the mutations on 
the enantioselectivity of Cal B. The bacterial cell pellets of each mutant were mechanically 
lysed according to the protocol described in section 2.8.2.2 and the total protein content of 
each sample was measured using the BCA assay. The crude cell free extracts from the lysis 
of the cell pellets were used in the biotransformation of ethyl-2-bromopropionate 123 
(Scheme 2.9). The substrate, ethyl-2-bromopropionate 123 (5 g/L), was added to potassium 
phosphate buffer (0.1 M, pH 7.0, 4 mL) containing ethanol (0.36 v/v%) to aid solubility of 
the substrate (Scheme 2.7). To start the reaction, 200 mg of protein (cell free extract) of 
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each mutant was added to the biotransformation reactions. The biotransformations were 
conducted at 30 °C and in total eight to ten samples of each biotransformation were taken 
at various time points for analysis using the reverse phase chiral HPLC method developed 
in section 2.8.2.1 (Table 2.14). The protein from each sample was removed by heat 
denaturisation at 95 °C for 5 minutes and then the degree of conversion and the e.e. of the 
supernatant recorded using the reverse phase chiral HPLC method outlined in Table 2.14. 
The conversion and e.e. of each sample were used to calculate the ER of the Cal B variants. 
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Scheme 2.9: Biotransformations of the hydrolysis of ethyl-2-bromopropionate 123 by the 
mutants of Cal B. 
Reaction conditions: ethyl-2-bromopropionate 123 (5 g/L), enzyme (200 mg/reaction), potassium phosphate 
buffer (100 mM, pH 7.0, 4 mL), ethanol (0.36% v/v), incubated in a 30 °C shaker. 
 
2.10.3 Enantioselectivity of Cal B mutants with single point mutations 
 
The enantioselectivity of each Cal B variant was calculated using the enantiomeric excess 
of the product (ee(P)), 2-bromopropionic acid 123, the degree of conversion (c) and 
Equation 6 (Appendix 7), as described by Chen et al.
163
 The ER of each sample was used to 
calculate an average ER of each mutant and the results are collated in Table 2.18. 
 
ER = ln[(1–c)(1+ee(P))] ÷ ln[(1–c)(1-ee(P))]  (6) 
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Mutant Thr40 Asp134 Thr138 Gln157 Ile189 Val190 Leu278 Ile285 
A 1.1 1.2 1.8 1.2 1.0 1.1 1.3 2.0 
C 1.0  2.0  1.2 1.1  2.0 
D 1.1 2.0 1.6   1.1  1.8 
E 1.1  1.2   1.1  1.1 
F     1.0 1.1  1.7 
G 1.1  1.7  1.2 1.0  1.2 
H   1.3  1.1 1.2  1.8 
I 1.0   1.1 2.0   2.0 
K 1.1  1.9   1.1  1.3 
L   1.6 1.7 1.1 1.6 2.0 2.9 
M 1.0  2.8   1.1  1.9 
N 1.1 1.1 1.3 1.7 1.0 1.5  2.2 
P 1.1    1.1 1.2  1.2 
Q 1.1  1.6 2.0 1.1 1.2  2.0 
R 1.1  1.3   1.1  1.3 
S 1.2 1.2 2.0 1.7 1.2 1.1  1.1 
T 2.0 1.3 2.0 1.0 1.2 1.1  2.1 
V   2.0 1.0 2.1 2.0  2.1 
W      1.1  1.7 
Y   1.4   1.0  1.0 
Yellow = Wild-type, Blue = (R)-selective, White = (S)-selective, Grey = not synthesised 
Table 2.18: The enantioselectivity of mutants of Cal B towards the kinetic resolution of the 
substrate ethyl-2-bromopropionate 123. 
 
2.10.3.1 Thr40 mutants 
 
The transition state of Cal B catalysed hydrolysis of esters involves generation of an 
oxyanion that is stabilised by a network of hydrogen bonds formed from the side chain of 
Thr40 and the amide backbone of Thr40 and Gln106.
158
 The stabilisation of the oxyanion 
hole has been attributed for the lowering of the free energy of the transition state.
192
 A 
hypothesis was proposed that mutations at position 40 would lead to decrease in rate of 
reaction and the results confirm this (Figure 2.31).  
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Figure 2.31: Relative rate of reaction of Thr40 mutants compared to wild-type Cal B in the 
kinetic resolution of ethyl-2-bromopionate 123. 
 
The effect of the mutations at this position on enantioselectivity is also pronounced with all 
mutants synthesised having lost all enantioselectivity, although whether this is as a result 
of a loss in rate of reaction and therefore conversion or due to loss of specific interactions 
between the enantiomers and the active site, has not been determined. The rates of reaction 
relative to the wild-type Cal B were significantly lower. Less than 40% of the original 
activity was retained in the mutants at position 40. This confirms the importance of Thr40 
as part of the hydrogen network that stabilises the oxyanion intermediate. When Thr40 was 
substituted for another nucleophilic amino acid, serine and cysteine, the rate of reaction 
and enantioselectivity could not be replicated. This result suggests that Cal B has evolved 
to incorporate threonine in position 40 and was necessary for activity for the kinetic 
resolution of ethyl-2-bromopropionate 123. 
 
2.10.3.2 Asp134 mutants 
 
Specific mutations at position 134 were chosen to reduce the steric clash between the 
active site wall and the large bromine atom in the (S)-enantiomer of the substrate ethyl-2-
bromopropionate 123. To this end, mutants with substitution of the Asp amino acid for 
smaller amino acids such as Ala were generated. All of the variants at position 134 showed 
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a decrease in enantioselectivity combined with a decrease in the rate of reaction, even for 
the mutant Asp134Ala (Table 2.18 and Figure 2.32) 
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Figure 2.32: The rate of reaction of Asp134 mutants compared to wild-type Cal B in the 
kinetic resolution of ethyl-2-bromopropionate 123. 
 
2.10.3.3 Thr138 mutants 
 
From the HPLC assay, all the Thr138 variants of Cal B were found to have a higher rate of 
reaction than wild-type Cal B (Figure 2.33). One variant, Thr138Met, was found to have a 
higher rate of reaction and a higher enantioselectivity (Table 2.18).  
 
The higher rate of reaction in the Thr138Ala mutant can be attributed to a reduction in the 
size of the amino acid from a threonine to an alanine. The enlarged space created in the 
Thr138Ala mutant can allow the substrate to move in and out of the active site readily 
thereby increasing activity.  
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Figure 2.33: Variants of Thr138 with a higher rate of reaction than the wild-type. 
 
2.10.3.4 Gln157 mutants 
 
The variants generated by mutation at position 157 gave rise to a library with opposite 
stereopreference to the wild-type. The specific mutations were chosen to increase space to 
accommodate the bromine atom of the (S)-enantiomer of 
ethyl-2-bromopropionate 123 and therefore activity towards this enantiomer. The results 
showed that the mutants exhibited a slower rate of reaction than the wild-type (Figure 
2.34). 
 
To account for the opposite stereopreference, models of the mutants of Gln157 were 
generated with both enantiomers of ethyl-2-bromopropionate 123 which showed that the 
space was increased, as was intended, but they could not show conclusively how 
enantioselectivity was affected. Although several mutants of Gln157 demonstrated 
opposite stereopreference, as a saturation library was not made of Gln157, it may not apply 
to the remaining variants of the library. Synthesis of the remaining variants will show 
whether this is a trend and models will aid the rationalisation of the trend. 
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Figure 2.34: Rate of reaction of mutants of position 157 with opposite stereopreference 
than the wild-type Cal B. 
 
2.10.3.5 Ile189 and Val190 mutants 
 
The Ile189 and Val190 libraries did not yield any mutants of significant interest. All the 
mutants generated in these 2 libraries had a lower rate of reaction and equal or lower 
enantioselectivity than the wild-type. When models of the mutants of position 189 were 
investigated, a large gap was demonstrated when compared to the wild-type. Although this 
fulfilled our original criteria of creating more space to accommodate the bromine atom of 
the (S)-enantiomer, creation of this larger void led to the loss of stereoselectivity due to the 
free movement of both enantiomers of the substrate ethyl-2-bromopropionate 123 in and 
out of the active site. Originally the large bromine of the (S)-enantiomer was restricted to a 
pocket of the active site, however enlarging the void has allowed the bromine of both 
enantiomers to fit in freely, thereby losing stereoselectivity (Figure 2.35). 
 
 115 
  
 
Figure 2.35: left – model of wild-type Cal B showing restriction of the bromine in a certain 
position.  
Right – model of Ile189Gly showing an enlarged space that no longer restricts the substrate 
to certain positions. 
 
2.10.3.6 Leu278Ala mutant 
 
The mutant Leu278Ala was included in this study as it was reported
190
 to have an 
increased rate of reaction for the hydrolysis of bulky substrates. Our results show this did 
not extend to our substrate ethyl-2-bromopropionate 123 as less than 40% of the original 
activity was observed in the Leu278Ala mutant (Figure 2.36). 
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Figure 2.36: Leu278Ala demonstrated a slower reaction rate than the wild-type for the 
kinetic resolution of ethyl-2-bromopropionate 123. 
 
2.10.3.7 Ile285 mutants 
 
Ile285 is the furthest amino acid residue from the active site and is positioned near the 
entrance to the active site. Surprisingly its effect has been the most pronounced with the 
identification of two mutants (Ile285Ala and Ile285Lys) with a faster rate of reaction and 
one mutant (Ile285Leu) with a higher enantioselectivity than the wild-type. When models 
of the mutants of position 285 were generated, the entrance to the active site changed in 
shape and in terms of electronic character. It was proposed that this affected the access of 
the substrate into the active site.  
 
2.10.4 Comparison of enantioselectivity of Ile285Leu, Thr138Ala and Thr138Met 
 
From the initial enantioselectivity screen, three mutants, Ile285Leu, Thr138Ala and 
Thr138Met, were chosen for further investigation due to the high rates of reaction or 
enantioselectivity they displayed. For a true comparison with the wild type, the 
biotransformations were repeated with 5 mg of protein (cell free extract) per mL added to 
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the reaction. Samples taken at specific time points were analysed using the method 
described in Table 2.14 (Figure 2.37 and 2.38). 
 
The results confirmed that all three mutants had a higher enantioselectivity than the wild-
type but the Thr138Met mutant had a significantly higher enantioselectivity. A model of 
the Thr138Met mutant was made with the (R)- and (S)-enantiomers of the intermediate 
docked into the active site. It showed that the bromine of the (R)-enantiomer sterically 
clashed with the Thr138Met mutation, thus making the (S)-enantiomer more favourable. 
The Thr138Met mutant positions the smaller methyl group next to the Thr138Met mutation 
(Figure 2.38).  
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Pink = Wild-type Cal B, Yellow = No enzyme, Green = T138M mutant, Red = T138A mutant, Blue = 
I285L mutant 
Figure 2.37: Product accumulation as a function of time for WT Cal B and the mutants 
Ile285Leu, Thr138Ala and Thr138Met. 
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Figure 2.38: Comparison of enantioselectivity of Ile285Leu, Thr138Ala and Thr138Met 
relative to wild-type Cal B. 
 
  
 
Figure 2.39: Molecular model of the Thr138Met mutant with the (S)-enantiomer of the 
intermediate docked into the active site. Model shows the Thr138Met mutant with the 
smaller methyl group of (S)-2-bromopropionic acid next to the Thr138Met mutation to 
reduce steric clashing. 
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3 Conclusion  
 
At the onset of this research programme, we hoped to identify commercially available 
lipases for the kinetic resolution of 2-bromopropionic acid 35 and 2-fluoropropionic acid 
83 for the synthesis of a number of enantiomerically pure chiral pharmacologically active 
compounds. Retrosynthetic analysis identified 2-bromopropionic acid 35 and 2-
fluoropropionic acid 83 as common intermediates. Additionally, optically active 2-
bromopropionic acid 35 could be used for the synthesis of other chiral starting materials.  
 
An initial screen of 16 lipases identified only one lipase, Cal B, able to kinetically resolve 
both 2-bromopropionic acid 35 and 2-fluoropropionic acid 83. The gene of Cal B was 
sourced and subcloned into two vectors, pET16b and pET SUMO, for expression in E. coli. 
After various investigations, Cal B was expressed from the pET16b vector in 2 types of E. 
coli competent cells, BL21 and Origami 2, the latter of which promotes disulfide bond 
formation in the cytoplasm of E. coli. The Cal B produced from the Origami 2 competent 
cells gave a Cal B with higher specific activity and was therefore used for future 
productions of Cal B.  
 
As the enantioselectivity of Cal B towards both substrates was poor, directed evolution was 
used for rational design of mutants with increased activity and higher enantioselectivity 
towards the substrates of interest. Problems with the stability of ethyl-2-fluoropropionate 
124 hampered further investigation into this substrate but Cal B mutants identified from 
structure-driven modelling were screened with the substrate ethyl-2-bromopropionate 123. 
A total of 89 mutants with single amino acid changes were generated with several mutants 
exhibiting higher rates of reaction than the wild type and with one mutant, Thr138Met, 
exhibiting a moderate increase in enantioselectivity. Finally, in addition to these, several 
variants of the 157 library were identified to having opposite enantiopreference.  
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4 Future work 
 
This project has laid the foundations for identifying variants of Cal B for the kinetic 
resolution of α-haloacids and esters. With the initial results from the single amino acid 
mutations, researchers in future should consider probing cooperative effects of mutations 
and utilising the iterative saturation mutagenesis strategy demonstrated by Reetz et al.
128 
Additionally having demonstrated sensitive residues relevant for this project, further work 
into probing adjacent amino acids should be included in future work. If mutants generated 
using rational design does not generate variants with the desired properties, other 
mutagenesis strategies should be utilised such as epPCR. 
 
Additional to using mutagenesis techniques for improving the properties of an enzyme, 
they can also be used to improve the expression of enzymes. The expression systems we 
presented in this thesis yield Cal B that is partially soluble. Cal B has many hydrophobic 
residues on its surface and this may increase the formation of inclusion bodies in the 
cytoplasm or block translocation during its secretion to the periplasm.
193
 Mutagenesis to 
introduce hydrophilic residues onto the surface of Cal B to increase the yield of functional 
expression of Cal B in E. coli can also be considered. To this end, substitution of residues 
Leu147, Leu199, Leu219, Leu261 and Ile255 with aspartate was carried out by Park et 
al.
194
 These substitutions resulted an increase in the expression yield of functional Cal B by 
a factor of three. The effect of these mutations on hydrolysis activity and enantioselectivity 
was also investigated and no significant differences to the wild-type were observed. 
 
Having successfully generated mutants of Cal B, the lack of a high throughput assay 
severely limited the numbers of mutants screened in this project. Addition of a solid-phase 
screen on tributyrin agar plates would eliminate inactive mutants generated when strategies 
such as epPCR are used. Further synthetic approaches towards enantiopure 4-nitrophenyl 
2-bromopropionate 118 and 4-nitrophenyl 2-fluoropropionate and 119 would also further 
reduce the number of mutants assayed using the HPLC assay described in this thesis. With 
these two pre-screens in place, the number of mutants needed to be grown up on a large 
scale for biotransformations and analysed by conventional HPLC would be manageable.  
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With these new strategies proposed, identification of a variant of Cal B with enhanced 
enantioselectivity properties should be forthcoming and then utilisation of the enantiopure 
α-haloacids and esters for the synthesis of pharmacologically active compounds such as 
(S)-Keppra (S)-32 and (R)-Tiopronin (R)-34, as well as other enantiopure starting materials, 
would complete the goals initially intended for this project. 
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5 Experimental 
 
5.1 General Procedure 
 
All HPLC chromatograms were recorded on an Agilent 1100 series instrument with an 
integrated Agilent 1200 series column temperature regulation compartment. The samples 
were run on a Daicel Chiralpak
®
 AD-H chiral column (19325) or an Astec Chirobiotic
TM
 T 
chiral column (12024AST). 
 
PCR reactions were performed in an Eppendorf Mastercycler
®
 Gradient. The 
concentrations of double stranded DNA (dsDNA) and protein to DNA ratio were recorded 
using an Eppendorf BioPhotometer with an 8.5 mm light centre height in RNase-/DNA-
/Protein-free Eppendorf disposable, single sealed cuvettes. Bacterial cells were harvested 
by centrifuge in an Eppendorf 5810R centrifuge and a table-top Eppendorf 5415R 
centrifuge was used for PCR and plasmid DNA purification. All 0.8% analytical agarose 
gels were run at 80 V for 45 minutes. Gel extraction was performed using an Invitrogen 
Safe Imager
TM
 transilluminator and SYBR Safe DNA gel stain. Incubation of reactions 
was performed in an Infors-HT Multitron II incubation shaker. 
 
Sterile technique was used through-out all molecular biology procedures where necessary.  
 
5.2 Chemicals and Reagents 
 
Standard chemicals for the preparation of buffers and media, as well as standard laboratory 
consumables were purchased either from BioRad (Hertfordshire, U.K.), Eppendorf U.K. 
Ltd. (Cambridge, U.K.), Eurofins MWG Operon (Ebersberg, Germany), Fisher Scientific 
U.K. Ltd. (Loughborough, U.K.), Fluorochem Ltd. (Derbyshire, U.K.), GE Healthcare 
(Buckinghamshire, U.K.), Invitrogen Ltd. (Paisley, U.K.), Merck Biochemicals Ltd. 
(Nottingham, U.K.), New England Biolabs Ltd. (Hertfordshire, U.K.), Pierce 
(Northumberland, U.K.), Qiagen Ltd. (West Sussex, U.K.), Romil Ltd. (Cambridge, U.K.), 
Sigma-Aldrich Company Ltd. (Gillingham, U.K.) or Stratagene (Texas, USA) and used as 
supplied unless stated otherwise.  
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5.2.1 Growth Media 
 
LB (Luria-Bertani) 
 
Broth medium was composed of tryptone (10g), NaCl (10g) and yeast extract (5g) 
dissolved in 1 L of distilled H2O (dH2O). Sterile LB media was supplied by the in-house 
media preparation service. 
 
LB Agar 
 
Medium was prepared according to the method outlined above but with the addition of 
agarose (15 g) in 1 L of dH2O. Sterile LB agar was supplied by the in-house media 
preparation service. 
 
SOC medium  
 
SOC medium (S1797) was purchased from Sigma-Aldrich Company Ltd and used as 
bought. 
 
5.2.2 LB agar plates 
 
LB agar plates containing ampicillin (LB amp) were prepared by melting a bottle of LB 
agar and cooling it to 55°C in a water bath. Ampicillin (1 µL per mL) was added and the 
plates were prepared by pouring into petri dishes. The LB amp plates were inverted and 
stored at 4°C. 
 
LB agar plates containing kanamycin (LB kan) were prepared by melting a bottle of LB 
agar and cooling it to 55°C in a water bath. Kanamycin (1 µL per mL) was added and the 
plates were prepared by pouring into petri dishes. The LB kan plates were inverted and 
stored at 4°C. 
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5.2.3 Buffers 
 
50x TAE Buffer 
 
TAE buffer was composed of 242 g tris base, 57.1 mL glacial acetic acid and 10 mL 0.5 M 
EDTA (pH 8.0) made up to a total volume of 1 L with dH2O. 
 
DNA loading buffer for electrophoresis 
 
DNA loading buffer was composed of 30% glycerol (v/v), 0.2% bromophenol blue, 25 
mM EDTA and was diluted with TAE.  
 
10x Tris-Glycine-SDS buffer for electrophoresis 
 
10x Tris-Glycine-SDS buffer (161-0772), purchased from Bio-Rad Laboratories UK, was 
composed of tris(hydroxymethyl)aminomethane (25 mM), glycine (192 mM) and  SDS 
(0.1%) and 100 mL was diluted with dH2O (900 mL). 
 
2x Laemmli sample buffer for electrophoresis 
 
2x Laemmli sample buffer (S3401) was purchased from Sigma-Aldrich Company Ltd. 
 
Potassium phosphate buffer 0.1 M pH 7.4  
 
Potassium phosphate buffer (0.1 M, pH 7.4) was prepared from dipotassium hydrogen 
phosphate buffer solution (1 M, 80.2 mL), potassium dihydrogen phosphate buffer solution 
(1 M, 19.8 mL) and dH2O (950 mL). 
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Western blotting buffers 
 
Phosphate buffered saline  
 
Phosphate buffered saline tablets (PBS, P4417) were purchased from Sigma-Aldrich 
Company Ltd. The tablets of PBS were composed of phosphate buffer (0.01 M), potassium 
chloride (0.0027 M) and sodium chloride (0.137 M) and were dissolved in dH2O (200 mL). 
 
Phosphate buffered saline solution with Tween 20 (0.05%) 
 
PBS with Tween 20 was composed of PBS (100 mL) and Tween 20 (50 µL, P7949) 
purchased from Sigma-Aldrich Company Ltd was added.  
 
Blocking buffer 
 
Blocking buffer was composed of casein protein (10 g) in PBS (200 mL). 
 
Blocking buffer with monoclonal Anti-polyHistidine−Peroxidase antibody 
 
The blocking buffer with monoclonal Anti-polyHistidine−Peroxidase antibody was 
composed of casein protein (1.25 g), PBS (25 mL) and monoclonal Anti-
polyHistidine−Peroxidase antibody produced in mouse (25 µL, A7058-1VL). The 
monoclonal Anti-polyHistidine−Peroxidase antibody produced in mouse (25 µL, A7058-
1VL) was purchased from Sigma-Aldrich Company Ltd. 
 
Towbin buffer 
 
Towbin buffer was prepared from Tris (3.03 g), glycine (14.4 g), methanol (100 mL) and 
dH2O (900 mL). 
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Purification buffers 
 
Binding buffer 
 
To sodium phosphate buffer (0.1 M, pH 8.0), NaCl (17.55 g/L) and imidazole (0.01 M, 
0.68 g/L) were added and the solution was filtered before use. 
 
Eluting buffer 
 
To sodium phosphate buffer (0.1 M, pH 8.0), NaCl (17.55g/L) and imidazole (1 M, 68.08 
g/L) were added and the solution was filtered before use. 
 
5.2.4 Stock solutions 
 
Ampicillin 
 
Stock solution of ampicillin sodium salt (1000 x) was prepared by dissolving 100 mg/mL 
of ampicillin in dH2O and sterilised by passage through a 0.22 µM syringe filter. These 
stock solutions were stored in 1 mL aliquots at – 20 °C until required. 
 
Kanamycin 
 
Stock solution of kanamycin (1000 x) was prepared by dissolving 50 mg/mL of kanamycin 
in dH2O and sterilised by passage through a 0.22 µM syringe filter. These stock solutions 
were stored in 1 mL aliquots at – 20 °C until required. 
 
Lysozyme 
 
Lysozyme solutions were prepared prior to use. Lysozyme (10 mg, L6876), purchased 
from Sigma-Aldrich Company Ltd., was dissolved in dH2O (1 mL) 
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para-Nitrophenyl acetate 
 
para-Nitrophenyl acetate (0.36 g, 20 mM) in dimethyl sulfoxide (100 mL) was prepared 
for use in the pNPA assay. 
 
para-Nitrophenyl butyrate 
 
para-Nitrophenyl butyrate (0.21 g, 20 mM) in dimethyl sulfoxide (100 mL) was prepared 
for use in the pNPB assay. 
 
3,3'-Diaminobenzidine (DAB) solution 
 
SigmaFast DAB (D4418) solution was purchased from Sigma-Aldrich Company Ltd. and 
used as described in protocol. 
 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) solution 
 
IPTG (11.92 g) in dH2O (50 mL) was prepared for use as stock solutions for the induction 
of cultures and sterilised by passage through a 0.22 µM syringe filter. 
 
5.2.5 Strains 
 
The bacterial strains used during this project are listed below and were stored at 
– 80 °C until required: 
 
E. coli Top10 
E. coli Mach1 T1-R 
E. coli BL21(DE3) 
E. coli Origami 2(DE3) 
E. coli XL1-Blue 
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5.2.6 Oligonucleotide primers 
 
Oligodeoxynucleotide primers for PCR-mediated cloning and sequencing were synthesised 
by Eurofins MWG Operon (Germany). 
 
5.2.7 Other 
 
DNA size markers for electrophoresis 
 
DNA size markers, 100 base pair (N3231S) and 1 kb DNA Ladder (N3232L), were 
purchased from New England Biolabs UK. 
 
 
PageRuler™ Prestained protein ladder for electrophoresis  
 
PageRuler™ Prestained protein ladder (SM0671), with a range of molecular weights from 
10 to 170 kDa, was purchased from Fermentas Life Sciences UK. 
 
5.3 Experimental details 
 
5.3.1 Initial hydrolase screen 
 
General procedure for the esterification of 2-bromopropionic acid and  
2-fluoropropionic acid 
 
The lipases (0.5 g/L) were weighed out into 7 mL glass vials with screw on caps 
containing a single molecular sieve (4 Å, 10 – 18 mesh). A stock solution was prepared 
containing iso-hexane (2 mL per reaction), substrate (5g per L) and n-butanol (5 equiv.). 
The stock solution was distributed equally per reaction and the reactions were incubated at 
30°C and shaken at 225 rpm for the length of the biotransformation.  
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General procedure for the BCA assay  
 
Stock solutions of the enzyme that were to be assayed were prepared and from the enzyme 
stock solution, 3 dilutions were made; 10:1, 100:1 and 1000:1.The BCA assay was 
prepared according to the manual (23225, Pierce BCA
TM
 protein assay kit). The BCA 
assay was completed in a microplate and 3 replicates of each assay were done. The end-
points of the standards and assay were measured at 584 nm on a plate reader.  
 
5.3.2 Cloning 
 
Transformation of the pPIC9 Cal B gene into One Shot Top10 competent cells 
 
pPIC9 Cal B
8998 bp
Alpha Factor
CalB
AmpR
HIS4
3' AOX1 Fragment
5 ' AOX1 promoter fragment
pBR322 origin
3 ' AOX1 TT
NcoI (4608)
NdeI (6832) Not I (2211)
Sac II (2076)
Sph I (5759)
Stu I (4238)
XbaI (3008)
XhoI (1193)
 
  
A vial of One Shot
® 
Top10 competent cells (50 µL) was thawed on ice prior to addition of 
0.5 µL pPIC9 Cal B DNA (200 ng/µL). The vial was incubated on ice for 30 minutes and 
then at 42°C, in a water bath, for 45 seconds to heat shock the competent cells into taking 
up the DNA. The vial was removed from the 42°C water bath and immediately placed into 
ice. To the vial, 250 µL of pre-warmed SOC medium was added before incubation at 37°C 
for 1 hour at 225 rpm. Two volumes of the transformation reaction were plated, 100 µL 
and 200 µL, onto LB amp plates. The plates were inverted and incubated at 37°C for 18 
hours.  
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General procedure for overnight cultures of successful transformation colonies 
 
A transformant was picked from the LB agar plates containing the appropriate antibiotic 
and inoculated into 5 mL aliquots of LB medium containing the same antibiotic to select 
for your expression plasmid. The overnight cultures were incubated at 37°C for 18 hours at 
225 rpm.  
 
General procedure for making glycerol stocks 
 
Glycerol stocks were prepared by combining 800 µL of the overnight culture with  
200 µL of glycerol. The samples were stored at – 80°C.  
 
General procedure for extracting and purifying plasmid DNA 
 
The remaining overnight culture samples were harvested by centrifugation at 4000 rpm for 
10 minutes. The supernatant was discarded and the bacterial cell pellet was dried by 
inversion of the tubes. The bacterial cell pellet was then purified using a Qiagen Plasmid 
Prep Kit (27106) as according to the manual.  
 
Restriction digest analysis of pPIC9 Cal B construct 
 
The restriction digest reactions contained 14 µL of dH2O, 3 µL of Buffer 2 (provided with 
restriction enzyme from NEB), 1 µL of BSA (10 mg/mL, provided with XbaI restriction 
enzymes), 10 µL of pPIC9 Cal B plasmid DNA, 1 µL of SphI restriction enzyme (20 U/μL) 
and 1 µL of XbaI restriction enzyme (20 U/μL). The reaction mixture was incubated at 37 
°C for 1.75 hours and was analysed on a 0.8% (w/v) agarose gel containing SYBR Safe 
DNA gel stain 10,000x concentrate in DMSO.  
 
General procedure for ethanol precipitation for sequencing 
 
To 1 µg of plasmid DNA, 10 µL of 10 M ammonium acetate and 125 µL of 100% pre-
chilled ethanol were added. The sample was submitted for centrifugation for 15 minutes at 
13,000 rpm. The supernatant was carefully pipetted off and 150 µL of 70% ethanol was 
 131 
added before it was centrifuged again for 15 minutes at 13,000 rpm. The supernatant was 
carefully removed again and the sample was air dried for 1 hour. 
 
PCR of the Cal B gene using designer primers for sub-cloning into pET 16b and 
Champion™ pET SUMO vectors 
 
To a mini eppendorf tube 5 µL of 10x Taq buffer, 5 µL of DMSO, 34 µL of dH2O,  
1 µL of dNTP mix (10 mM), 1 µL DNA template (50 ng/ µL), 3 µL of a mix of the 
forward and backward primers (100 µM) and 1 µL of Taq polymerase (20 U) were added 
(Table 5.1). Five samples of each of the two vectors in the reaction mixture were prepared 
and they were placed in a thermocycler PCR machine with the conditions set out below 
(Table 5.2). The PCR reaction was analysed on a 0.8% agarose gel containing SYBR Safe 
DNA gel stain 10,000x concentrate in DMSO. The PCR product was then purified using a 
QIAquick PCR purification kit (Qiagen PCR purification kit) as according to the manual. 
 
Primer DNA sequence 5’ – 3’ 
pET 16b forward sequence CGA GTC CAT ATG CGT CTA CCT 
TCC GG 
pET 16b backward sequence TGA TCG CTC GAG TTA GGG GGT 
GAC G 
pET SUMO forward sequence ATG CGT CTA CCT TCC G 
pET SUMO backward sequence TTA GGG GGT GAC GAT GC 
 
Table 5.1: Primers for cloning into the vectors Champion™ pET SUMO and pET 16b. 
 
Step Temperature °C Time/ mins  
1 95 3  
2 95 
50 
68 
1 
1 
3 
30 
cycles 
3 
4 
5 68 10 
 
6 4 hold 
  
Table 5.2: PCR reaction conditions. 
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Double digestion of the amplified Cal B gene and pET 16b vector 
 
To 1 µg of each of the purified insert and vector, 5 µL of 10x Buffer 4 (provided by NEB 
with the restriction enzymes), 1 µL of NdeI (20 U/μL), 1 µL of XhoI (20 U/µL), 0.5 µL of 
BSA (10 mg/mL) and 26.5 µL of dH2O were added. The reaction mixtures were incubated 
at 37 °C for 3 hours. An analysis gel (0.8% agarose gel) was run to monitor the reaction 
which was judged to be complete after 3 hours. The reaction mixtures were then run on a 
0.8% agarose gel and extracted under a blue light transilluminator and purified using a 
QIAquick Gel Extraction Kit according to the manual. 
 
Sub-cloning the Cal B gene into pET 16b vector  
 
pET 16b Cal B
6668 bp
AmpR
lacI
CalB
T7lac
BglII (1454)
EcoRI (6666)
Mlu I (2176)
NcoI (1349)
NdeI (1288)
Sac II (464)
Sph I (1651)
XbaI (1388)
XhoI (324)
 
 
Two ligation reactions were set up with a 1:1 ratio of insert to vector and 3:1 ratio of insert 
to vector. The 1:1 insert to vector reaction mixture contained 1 µL of insert (4 µg/mL), 8.3 
µL of pET 16b vector (3 µg/mL), 2 µL of T4 buffer, 5.7 µL of ultrapure water and 1 µL of 
T4 ligase (20 U/μL). The 3:1 insert to vector reaction mixture contained 3 µL of insert (4 
µg/mL), 8.3 µL of pET 16b vector (3 µg/mL), 2 µL of T4 buffer, 5.7 µL of ultrapure water 
and 1 µL of T4 ligase (20 U/μL). Both reaction mixtures were incubated at 4 °C for 4 days.  
 
Transformation of One Shot
®
 BL21 competent cells with pET 16b Cal B  
 
Two vials of One Shot
® 
BL21 competent cells (50 µL) were thawed on ice prior to addition 
of 1 µL of each of the ligation reactions (1:1 and 3:1 ratio of insert to vector). The vials 
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were incubated on ice for 30 minutes and then at 42°C, in a water bath, for 45 seconds to 
heat shock the competent cells into taking up the DNA. The vials were removed from the 
42°C water bath and immediately placed into ice. To the vials,  
250 µL of pre-warmed SOC medium was added before they were incubated at 37°C for 1 
hour at 225 rpm. Two volumes of the transformation reaction were plated, 50 µL and 100 
µL, onto LB amp plates. The plates were inverted and incubated at 37°C for 18 hours.  
 
Sub-cloning of the Cal B gene into Champion™ pET SUMO 
 
 
 
Two ligation reactions were set up with a 1:1 ratio of insert to vector and 3:1 ratio of insert 
to vector. The 1:1 insert to vector reaction mixture contained 1 µL of insert (11 µg/mL), 2 
µL of Champion™ pET SUMO vector (25 µg/mL), 1 µL of T4 buffer, 5 µL of ultrapure 
water and 1 µL of T4 ligase (20 U/μL). The 3:1 insert to vector reaction mixture contained 
3 µL of insert (11 µg/mL), 2 µL of Champion™ pET SUMO vector (25 µg/mL), 1 µL of 
T4 buffer, 5 µL of ultrapure water and 1 µL of T4 ligase (20 U/μL). Both reaction mixtures 
were incubated at 4°C for 18 hours.  
 
 
 
pET-SUMO Cal B 
6603 bp 
Cal B 
SUMO 
His Tag 
Kanamycin Resis. Gene 
lacI 
T7 lac promoter 
pBR322 ori 
Bam HI (815) 
Eco RI (572) 
RV (5625) 
Mlu I (6071) Nde I (296) 
Pst 
Sac II (1481) 
Sph I (1) 
Xba I (256) 
I (1509) 
Eco 
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Transformation of the pET SUMO Cal B construct into Mach1 T1-R competent cells 
for propagation 
 
Two vials of One Shot
® 
Mach1 T1-R competent cells (50 µL) were thawed on ice prior to 
addition of 2 µL of each of the ligation reactions (1:1 and 3:1 ratio of insert to vector). The 
vials were incubated on ice for 30 minutes and then at 42°C, in a water bath, for 45 
seconds to heat shock the competent cells into taking up the DNA. The vials were removed 
from the 42°C water bath and immediately placed into ice. To the vials, 250 µL of pre-
warmed SOC medium was added before they were incubated at 37°C for 1 hour at 225 rpm. 
Two volumes of the transformation reaction were plated, 50 µL and 100 µL, onto LB kan 
plates. The plates were inverted and incubated at 37°C for 18 hours.  
 
Restriction digest analysis to confirm the orientation of the gene in pET 16b Cal B 
and pET SUMO Cal B plasmid DNA 
 
Two restriction digest analysis reactions were set up. One eppendorf tube contained 14 µL 
of dH2O, 3 µL of BamHI buffer (provided with restriction enzyme from NEB), 1 µL of 
BSA (10 mg/mL, provided with appropriate restriction enzymes), 10 µL of pET SUMO 
Cal B plasmid DNA, 1 µL of SphI restriction enzyme (20 U/μL) and 1 µL of BamHI (20 
U/μL) restriction enzyme. The second eppendorf tube consisted of 15 µL of dH2O, 3 µL of 
Buffer 2 (provided with restriction enzyme from NEB), 10 µL of pET 16b Cal B plasmid 
DNA, 1 µL of MlnI restriction enzyme (20 U/μL) and 1 µL of SacII restriction enzyme (20 
U/μL). The reaction mixtures were incubated at 37°C for 3 hours. The reactions were 
analysed on a 0.8% (w/v) agarose gel containing SYBR Safe DNA gel stain 10,000x 
concentrate in DMSO.  
 
Transformation of One Shot
®
 BL21 competent cells with pET SUMO Cal B 
 
A vial of One Shot
® 
BL21 competent cells (50 µL) was thawed on ice prior to addition of 1 
µL pET SUMO Cal B plasmid DNA (42 µg/mL). The vial was incubated on ice for 30 
minutes and then at 42°C, in a water bath, for 45 seconds to heat shock the competent cells 
into taking up the DNA. The vial was removed from the 42°C water bath and immediately 
placed into ice. To the vial, 250 µL of pre-warmed SOC medium was added before it was 
incubated at 37°C for 1 hour at 225 rpm. Two volumes of the transformation reaction were 
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plated, 75 µL and 150 µL, onto LB kan plates. The plates were inverted and incubated at 
37°C for 18 hours.  
 
5.3.3 Protein production 
 
Transformation of Origami 2 competent cells with pET 16b Cal B 
 
A vial of Origami 2 competent cells (200 µL) was thawed on ice prior to sub-dividing into 
aliquots (20 µL). To a thawed aliquot of Origami 2 competent cells 1 µL of pET 16b Cal B 
was added. The vials were incubated on ice for 5 minutes and then at 42°C, in a water bath, 
for 30 seconds to heat shock the competent cells into taking up the DNA. The vials were 
removed from the 42°C water bath and immediately placed into ice for 3 minutes. To the 
vials, 80 µL of pre-warmed SOC medium was added before they were incubated at 37°C 
for 1 h at 250 rpm. Two volumes of the transformation reaction were plated, 20 µL and 50 
µL, onto LB amp plates with volumes less than 25 µL being added to a pool of SOC 
medium (50 µL) before spreading. The plates were incubated at rt for 15 minutes before 
inverting and incubating at 37°C for 24 h.  
 
General procedure for overnight cultures of successful transformation colonies 
 
A transformant was picked from the LB agar plates containing the appropriate antibiotic 
and inoculated into 5 mL aliquots of LB containing the same antibiotic to select for your 
expression plasmid. The overnight cultures were incubated at 37°C for 18 h for BL21(DE3) 
E. coli and for 24 h for Origami 2(DE3) E. coli at 250 rpm. 
 
Expression of pET 16b Cal B in Origami 2 E. coli 
 
LB amp (500 mL) was inoculated with the overnight culture (5 mL). The culture was 
allowed to grow to an OD600 of 0.6 in a 37 °C shaking (250 rpm) incubator. Once the cells 
had grown to the correct optical density, IPTG (1 M, 500 µL) was added and the cells were 
incubated at 16 °C for 24 h. The cells were harvested by centrifugation at 8,000 rpm, 4 °C 
for 20 min. 
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Expression of pET 16b Cal B in BL21 E. coli 
 
LB amp (500 mL) was inoculated with the overnight culture (5 mL). The culture was 
allowed to grow to an OD600 of 0.6 in a 37 °C shaking (250 rpm) incubator. Once the cells 
had grown to the correct optical density, the cells were incubated at 30 °C or 16 °C for 18 
h or 24 h. The cells were harvested by centrifugation at 8,000 rpm, 4 °C for 20 min. 
 
General procedure for the chemical lysis of bacterial cell pellets 
 
The bacterial cell pellet (1 g) was resuspended in BugBuster protein extraction reagent (5 
mL). To the solution, protease inhibitor cocktail (P8849, 50 µL), purchased from Sigma-
Aldrich Company Ltd., and lysonase (71230-4, 10 µL), purchased from Merck Biosciences 
Ltd., were added and the reaction mixture was allowed to mix at rt for 20 minutes before 
centrifuging at 20,000 rpm and 4 °C for 20 minutes. The cell free extract was decanted 
from the cell pellet. 
 
General procedure for the mechanical lysis of bacterial cell pellets 
 
The bacterial cell pellet (1 g) was resuspended in potassium phosphate buffer (pH 7.4, 0.1 
M, 5 mL) before addition of protein inhibitor cocktail (P8849, 50 µL), purchased from 
Sigma-Aldrich Company Ltd,  and lysozyme (L6876, 10 µL of 10 mg in 1mL of H2O). 
The reaction was incubated at 37 °C for 20 minutes before incubating in ice and sonicating 
for 15 seconds on, 15 seconds off for 3 cycles. 
 
General procedure for SDS-PAGE and Western blot 
 
To 2x Laemmli sample buffer (S3401, 20 µL), sample (20 µL) was added. The reaction 
was heated at 95 °C for 5 minutes before applying onto a Criterion Tris-HCl precast gel 
(Bio-Rad Laboratories UK). The gel was run at 150 mA for 80 minutes.  
 
For a Western blot, the SDS-gel and 2 sheets of blotting paper were incubated in cold 
Towbin buffer for 5 minutes. The PVDF membrane was first incubated in methanol for 5 
minutes before incubating in Towbin buffer for 5 minutes. The materials were arranged in 
the blotter as follows: blotting paper, PVDF membrane, SDS-gel and blotting paper. The 
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air bubbles were rolled out of the stack and excess liquid removed before blotting at 150 
mA for 70 minutes. After blotting, the SDS-gel was stained for 15 minutes at rt. The PVDF 
membrane was incubated in blocking buffer overnight at 4 °C. The membrane was then 
washed 3 times with PBS with Tween 20 and then once with PBS. The membrane was 
then incubated in blocking buffer with monoclonal Anti-polyHistidine−Peroxidase 
antibody for 1.5 h before washing again with PBS with Tween 20 3 times and once with 
PBS. The membrane was then incubated in SigmaFast 3,3'-diaminobenzidine solution for 5 
minutes. The membrane was dried before handling. 
 
General procedure for protein purification on the ÄKTA Explorer 100 FPLC 
 
A HiTrap Chelating HP affinity column was washed with filtered dH2O (5 column 
volumes) at a “drop to drop” rate then the metal ion solution (0.1 M, NiSO4 or CuSO4, 0.5 
mL) was applied. The column was equilibrated with water (5 column volumes) and then 
the syringe filtered cell free extract was applied. The column was then attached to the 
equilibrated ÄKTA Explorer 100 FPLC and the method run. The fractions (1 mL) were 
collected in a 96 well plate and stored at 4 °C.  
 
To concentrate and to desalt a sample for use in the pNPA assay, the fractions containing 
Cal B were combined before concentrating to 3 mL in a Vivaspin column with a 30,000 
molecular weight cut-off. The concentrated sample was then applied to a prepared PD10 
column. The protein was eluted off the PD10 column with potassium phosphate buffer (pH 
7.4, 0.05 M, 3 mL) and used in the pNPA assay and BCA assay. 
 
5.3.4 Testing the activity of recombinant Cal B 
 
General procedure for the esterification of 2-bromopropionic acid and  
2-fluoropropionic acid using recombinant Cal B 
 
A stock solution was prepared containing iso-hexane (2 mL per reaction), substrate (5g per 
L) and n-butanol (5 equiv.). The stock solution was distributed equally into 7 mL glass 
vials with screw on caps containing a single molecular sieve (4 Å, 10 – 18 mesh) per 
reaction. The biotransformations were started by addition of recombinant Cal B (10 or 100 
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μL of cell free extract) and the reactions were incubated at 30°C and shaken at 225 rpm for 
the length of the biotransformation.  
 
General procedure for the pNPA assay 
 
To each well enzyme preparation (5 µL) was added into potassium phosphate buffer (pH 
7.4, 0.05 M, 185 µL). The pNPA substrate (0-80 mM, 10 µL) was added prior to 
monitoring at 405 nm for 200 cycles. 
 
5.3.5 High throughput enantioselective screen development 
 
Synthesis of 4-nitrophenyl 2-bromopionate 118 
 
O2N
O
O
Br
12
3
3
4
4  
 
2-Bromopropionyl chloride (5 mL, 49.6 mmol) was added dropwise to a vigorously stirred 
solution of sodium 4-nitrophenoxide (7.26 g, 45.1 mmol) in 1 N sodium hydroxide (54.2 
mL, 54.2 mmol) and water (300 mL) cooled in an ice bath. The mixture was allowed to stir 
in the ice bath for 5 minutes and the precipitate was collected under vacuum filtration and 
washed with water. The title compound 118 (1.87 g, 14%) was obtained by crystallisation 
from cyclohexane as a white solid (m.p. 41-43 °C). 
1
H NMR (400 MHz, 298 k, CDCl3): δ 
= 1.41 (3H, d, J = 6.8), 4.1 (1H, q, J = 6.8), 7.6 (2H, C3H, dd), 8.2 (2H, C4H, dd). 
 
5.3.6 Characterisation of the different preparations of Cal B 
 
General procedure for the pNPB assay 
 
To each well enzyme preparation (5 µL) was added into potassium phosphate buffer (pH 
7.4, 0.05 M, 185 µL). The pNPB substrate (0-80 mM, 10 µL) was added prior to 
monitoring at 405 nm for 200 cycles. 
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5.3.7 Molecular modelling 
 
All modelling studies were prepared using Accelrys Discovery Studio 2.0. Substrates, 2-
bromopropionic acid, 2-fluoropropionic acid and ethyl-2-bromopropionate, were docked 
into the active site of wild-type Cal B using Accelrys Discovery Studio 2.0 software. The 
docking studies were performed with the help of Dr. K. Bailey and Dr. S. Willies. 
 
5.3.8 Genetic modification 
 
Protein engineering of Cal B 
 
The gene encoding Cal B, within a pET 16b expression plasmid, was subjected to 
mutagenesis of targeted amino acids (Thr40, Asp134, Thr138, Gln157,  Ile189, Val190, 
Leu278 and Ile 285). The saturation mutagenesis was prepared using the Stratagene 
QuikChange
®
 Site-directed Mutagenesis Kit, according to the manufacturer‟s instructions 
and the forward and backward primers were designed using the QuikChange
®
 Primer 
Design Program and adhering to the rules specified in the Stratagene QuikChange
®
 Site-
directed Mutagenesis Kit manual. 
 
To a mini eppendorf tube 5 µL of 10x Taq buffer, 1 µL forward primer (125 ng/µL), 1 µL 
backward primer (125 ng/µL), 40 µL of dH2O, 1 µL of dNTP mix (10 mM), 1 µL DNA 
template (50 ng/µL), and 1 µL of PfuTurbo DNA polymerase (2.5 U/μL) were added. Each 
of the PCR reactions was prepared and they were placed in a thermocycler PCR machine 
with the conditions set out below (Table 5.23). 
 
Step Temperature °C Time/ mins  
1 95 3  
2 95 
55 
68 
0.5 
1 
7 
16 
cycles 
3 
4 
5 68 10 
 
6 4 hold 
 
Table 5.3: PCR reaction conditions. 
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After PCR amplification, the DpnI restriction enzyme (20 U/μL) was added to digest the 
parental supercoiled dsDNA at 37 °C for 1 h, before inactivation of the restriction enzyme 
at 80 °C for 20 mins. The DNA containing the mutations were then used to transform E. 
coli XL1-Blue supercompetent cells. Transformants were then plated out on LB amp plates 
and individual colonies were picked and used to inoculate LB amp (5 mL of LB amp). The 
cultures were grown overnight at 37 °C before harvesting the cells by centrifugation. The 
bacterial cell pellet was then purified using a Qiagen Plasmid Prep Kit as according to the 
manual. The DNA was then sent for sequencing (Appendix 8 – Sequencing primers). 
 
DNA samples containing the correct mutation were used to transform E. coli Origami 2 
competent cells. Transformants were then plated out on LB amp plates and individual 
colonies were picked and used to inoculate LB amp (5 mL of LB amp). The cultures were 
grown overnight at 37 °C before being used to inoculate fresh media for production of 
protein. The cultures were grown at 37 °C to an OD600 of  
~ 0.6 before addition of IPTG (1 M, 500 µL) and incubation of the cells at 16 °C for 24 h. 
The cells were harvested by centrifugation at 8,000 rpm, 4 °C for 20 minutes before 
mechanical lysing. The cell free extract was used directly for biotransformation reactions. 
 
The substrate, ethyl-2-bromopropionate 123 (5 g/L), was added to potassium phosphate 
buffer (0.1 M, pH 7.0, 4 mL) containing ethanol (0.36 v/v%). The enzyme was added to 
start the reaction; biocatalysis was carried out at 30 °C and 250 rpm in a thermoshaker. 
Samples (100 μL) were taken at various time points and subjected to denaturisation at 95 
°C for 5 mins and then centrifugation. The supernatant was analysed by reverse phase 
chiral HPLC.  
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7 Appendices 
  
Appendix 1 Rate of conversion for 2-bromopropionic acid 
 
Equation 1  Conversion = (Aprod/ε) † ((Asub/ε) + (Aprod/ε)) 
 
where: 
ε is the molar extinction coefficient of 2-bromopropionic acid 
Aprod is the total area under product peaks 
Asub is the total area under substrate peaks 
 
Appendix 2 Enantiomeric excess 
 
Equation 2  
 
ee =  conc. of the (S)-enantiomer – conc. of the (R)-enantiomer 
               conc. of the (S)-enantiomer + conc. of the (R)-enantiomer 
 
Appendix 3 Selectivity E for kinetic resolution calculated from the enantiomeric 
excess of the substrate 
 
 
Equation 3 E = ln[(1–c)(1-ee(S))] ÷ ln[(1–c)(1+ee(S))] 
 
where: 
c is the conversion 
ee(S) is the enantiomeric excess of the substrate 
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Appendix 4 Rate of conversion for 2-fluoropropionic acid 
 
Equation 4 Conversion = (([blank]/ε)-([substrate]/ε)) † ([blank]/ε) 
 
 where: 
ε is the extinction coefficient of 2-fluoropropionic acid 
[substrate] is the concentration of 2-fluoropropionic acid in mg/mL 
[blank] is the concentration of 2-fluoropropionic acid in mg/mL in the 
biotransformation reaction with no enzyme 
 
Appendix 5 ng of insert to vector to use 
 
Equation 5 
 
Ng of insert = ng of vector × (kb of insert / kb of vector) × ratio of insert to vector 
 
Appendix 6 Amino acids 
 
H2N CO2H
H H
H2N
CH3
CO2H H2N CO2H
Smaller amino acids Nucleophilic amino acids
OH
H2N CO2H
OH
H2N CO2H
SH
H2N CO2H
Hydrophobic amino acids
H2N CO2H H2N CO2H H2N CO2H
S
N
H
CO2H
Aromatic amino acids
H2N CO2H H2N CO2H
OH
H2N CO2H
NH
Glycine (Gly, G) Alanine (Ala, A) Serine (Ser, S) Threonine (Thr, T) Cysteine (Cys, C)
Valine (Val, V) Leucine (Leu, L) Isoleucine (Ile, I) Methionine (Met, M) Proline (Pro, P)
Phenylalanine (Phe, F) Tyrosine (Tyr, Y) Tryptophan (Trp, W)
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H2N COOH
H H
H2N
CH3
COOH H2N COOH
Smaller amino acids Nucleophilic amino acids
OH
H2N COOH
OH
H2N COOH
SH
H2N COOH
Hydrophobic amino acids
H2N COOH H2N COOH H2N COOH
S
N
H
COOH
Aromatic amino acids
H2N COOH H2N COOH
OH
H2N COOH
NH
H2N COOH
OH
O
Acidic amino acids
H2N COOH
O OH
H2N COOH
NH2
O
H2N COOH
O NH2
Amides
H2N COOH
Basic amino acids
NH
HN
H2N COOH
NH3
H2N COOH
NH
NH2H2N
Glycine (Gly, G) Alanine (Ala, A) Serine (Ser, S) Threonine (Thr, T) Cysteine (Cys, C)
Valine (Val, V) Leucine (Leu, L) Isoleucine (Ile, I) Methionine (Met, M) Proline (Pro, P)
Phenylalanine (Phe, F) Tyrosine (Tyr, Y) Tryptophan (Trp, W)
Aspartic acid (Asp, D) Glutamic acid (Glu, E) Asparagine (Asn, N) Glutamine (Gln, Q)
Histidine (His, H) Lysine (Lys, K) Arginine (Arg, R)  
  
Appendix 7 Selectivity E for kinetic resolution calculated from the enantiomeric 
excess of the product 
 
Equation 6 ER = ln[(1–c)(1+ee(P))] ÷ ln[(1–c)(1-ee(P))]  
 
where: 
c is the conversion 
ee(P) is the enantiomeric excess of the product 
 
Appendix 8 Primers for sequencing mutants of Cal B 
 
Position Primer sequence 
Thr40 T7 forward standard primers 
Asp134, Thr138 and Gln157 GCGCAGCTGGGTTACACACC 
Ile 189 and Val190 
GTTGCACAGTGGGGTCTGACC 
Leu278 and Ile 285 T7 reverse standard primers 
 
